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A. Summary 
In this study we could show the biosynthetic potential of the genus Streptomyces by sequencing the 
genome of Streptomyces fulvissimus, which revealed 32 putative biosynthetic gene clusters. We were 
able to elucidate the biosynthesis of the macrodiolide antibiotic pamamycin by knocking out 
responsible genes in the pamamycin biosynthetic cluster and analyzing the resulting intermediates. We 
could show that succinyl-CoA is utilized as a starter unit and either malonyl-CoA, methylmalonyl-
CoA or ethylmalonyl-CoA are used as extender units in pamamycin biosynthesis. The knowledge of 
the pamamycin biosynthesis was used to engineer our heterologous host, the model organism 
Streptomyces albus J1074, in a specific direction. We focused our efforts to reduce or abolish the 
cellular concentration of methylmalonyl-CoA and ethylmalonyl-CoA in S. albus J1074 to reduce the 
compound spectrum of produced pamamycins. We could greatly influence the compound spectrum 
and we could identify the bottleneck of pamamycin production as succinyl-CoA. We could also prove 
that the metabolism of valine is the sole provider for the biosynthesis of pamamycin. Furthermore we 
could show the dependency of antibiotic production on gene dosage and we could increase the 
production of several secondary metabolites by increasing the number of clusters present on the 
genome. 
B. Zusammenfassung 
Wir konnten das genetische Potential des Genus Streptomyces anhand der kompletten Genom-Sequenz 
von Streptomyces fulvissimus, der 32 putative Biosynthese-Gencluster besitzt, zeigen. Außerdem 
konnten wir die Biosynthese des Makrodiolid-Antibiotikums Pamamycin aufklären, indem die für die 
Biosynthese verantwortlichen Gene ausgeknockt und die daraus entstandenen Intermediate 
nachgewiesen wurden. In der Pamamycin-Biosynthese wird Succinyl-CoA als Startereinheit 
verwendet, auf welche entweder Malonyl-CoA, Methylmalonyl-CoA oder Ethylmalonyl-CoA als 
weitere Bausteine folgen können. Dieses Wissen nutzten wir, um unseren heterologen Stamm 
Streptomyces albus J1074 gezielt zu verändern. Unser Ziel war es, die intrazellulären Konzentrationen 
von Methylmalonyl-CoA und Ethylmalonyl-CoA in S. albus zu verringern um das Substanzspektrum 
der produzierten Pamamycine einzuschränken. Wir konnten das Substanzspektrum der produzierten 
Pamamycine stark beeinflussen, dadurch Succinyl-CoA als den limitierenden Faktor der Biosynthese 
identifizieren, und nachweisen, dass sich die Pamamycin-Biosynthese ausschließlich aus dem 
Metabolismus von Valin speist. Durch das Einbringen mehrerer Biosynthesegencluster in denselben 
genetischen Hintergrund konnten wir die Produktion verschiedener Antibiotika steigern und dadurch 
zeigen, dass die Sekundärstoffproduktion von der Anzahl der Gencluster abhängig ist.  
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I. Introduction 
1. Natural products  
Natural products are a part of the human society since the early beginning. Either as ointments made 
from plants, poisons from animals or antibiotics from microorganisms. In general, natural products are 
substances isolated from various organisms. They are either products of the primary or secondary 
metabolism. Substances from the primary metabolism (polysaccharides, proteins, nucleic and fatty 
acids) are present in all biological systems. Substances from the secondary metabolism (secondary 
metabolites) are often produced exclusively by a certain group of organisms and are usually low-
molecular-weight (MW < 3000) and chemically diverse substances with many biological applications. 
Antibiotics belong to the natural products family originating from the secondary metabolism and are 
produced mostly by bacteria or fungi (Berdy 2005). 
2. Antibiotics 
Antibiotics are low-molecular-weight (MW < 2000) metabolites produced by microorganisms in a 
step-by-step biosynthesis. They inhibit growth of other microorganisms in low concentrations (< 200 
µg/ml) (Waksman & Fennes F. 1949). The definition of antibiotics has since then been extended to 
include also natural products with various structures produced by the secondary metabolism of living 
organisms and synthetic substances which show inhibitory activity against microorganisms (Lanzini & 
Lorenzeti 1993). Naturally produced antibiotics derive from the secondary metabolism and are thus 
not essential for growth and replication. Nevertheless they provide an advantage for the producer 
under unfavorable living conditions (Davis 1990). Antibiotic production often starts after reaching the 
stationary phase of growth or after reaching a growth-optimum (Bu" Lock et al. 1965). The genes 
responsible for production of individual secondary metabolites in bacteria are almost always located 
together in the genome and are referred to as biosynthetic gene clusters (Doroghazi & Metcalf 2013). 
The golden age of antibiotics spanned the 1940s and 1950s (Clardy et al. 2006). During this time, 
nearly all known groups of antibiotics have been discovered: β-lactams, tetracyclins, 
chloramphenicols, aminoglycosides, macrolides, aminocoumarines, glycopeptides, macrolactams and 
streptogramines. Since then, the only new classes of antibiotics which have been approved for therapy 
were avermectins (in 1989) and daptomycin (in 2003) Antibiotics have originally been developed for 
clinical use to treat infectious diseases. The various types of compounds discovered so far do not often 
show antibacterial activity, but instead activities against fungi, insects, herbs or even cancer cells. 
Therefore antibiotics have been applied not only in clinical therapy but also as food additives, as 
fungicides, herbicides or insecticides for plant protection or in veterinary use. 
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3. Antibiotic resistance 
After having approved a new antibiotic for clinical use, emergence of resistant bacteria to this specific 
antibiotic is inevitable. This is quite coherent because of the short replication time of bacteria and their 
typical mutation rate of 1 in 107 bacteria. The time period for bacteria to become resistant can vary 
among one year for penicillin V and up to 30 years for vancomycin (Walsh & Wright 2005). But 
people still see it as given that antibiotics are present to treat infections (Nathan 2004). Therefore new 
antibiotics have to be developed continuously. However, the antimicrobial pipeline for new 
therapeutics is now drying up. Nowadays, the big pharma companies have abandoned the research 
programs devoted to new antimicrobial compounds, and rather focus on more profitable fields like 
chronic diseases or affective dysfunctions (Leeb 2004). 
The most usual causes for development or spreading of a resistance are the use of antibiotics as a 
performance-enhancing drug in livestock farming, as a feed additive for poultry to suppress bacterial 
infections caused by factory farming, the premature termination of an antibiotic therapy, wrong 
diagnosis of an infection or long term antibiotic treatment after surgery. Infections which could be 
treated in a few days by antibiotics, like pneumonia, have to be treated for months or in some cases 
prophylactic nowadays (Zähner & Fiedler 1995). 
The most important resistance mechanisms include the inactivation of the drug by enzymes, the 
modification of the drug target and the activation of drug efflux pumps. Hydrolysis of β-Lactams is an 
example for drug inactivation by enzymes. Vancomycin resistant enterococci (VRE) protect 
themselves by modification of the drug target which causes a loss in affinity of the drug to the target. 
Efflux-pumps from the class of the ABC-transporters are used as active transportation mechanisms to 
reduce the antibiotic concentration to a sub-toxic level (Walsh & Wright 2005). Because of these 
problems it is of greatest importance to search continuously for new antibiotics and to approve them 
for clinical use.  
4. Screening for new compounds 
Classical screening for antibiotics was very successful between 1950 and 1960, but the chances for 
success are limited nowadays, because of the high rediscovery rate of already known compounds. 
Probably every year over a million of microorganisms are screened for antibiotic production, and most 
of the time the same screening-methods and the same microorganisms (Streptomyces and other 
actinobacteria, lower fungi, Bacillus, Pseudomonas, etc.) are used. After having applied this screening 
method for over 50 years, it is not surprising that from a huge pile of known compounds only a few 
new substances are discovered (Zähner & Fiedler 1995).  
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Nevertheless, the traditional search for antibiotics can be improved by using taxonomical methods for 
dereplication of the isolates and by applying taxonomical insights for cultivation and screening for 
active metabolites (Goodfellow & Fiedler 2010). The endeavor to screen Streptomyces species for new 
antibiotics should pay off, if one considers that only a small amount of antibiotics produced by 
Streptomyces species have been discovered. Watve et al. (2001) predicted that the 3000 known 
compounds produced by Streptomyces roughly account only for about 2 % of the potential products. 
With this in mind, around 98 % of hidden potential still remains undiscovered. This assumption is 
supported by the whole genome sequence of the model organism Streptomyces coelicolor A3(2) 
(Bentley et al. 2002) and Streptomyces avermitilis (Ikeda et al. 2003). Both genomes encode a large 
number of putative biosynthetic gene clusters which are not expressed under standard laboratory 
conditions. These gene clusters are referred to as cryptic or silent. Also other actinobacteria like 
Saccharopolyspora erythraea (Oliynyk et al. 2007) with 25 secondary metabolite gene clusters show 
high biosynthetic potential. These findings led many researchers to predict a renaissance for antibiotic 
discovery by genome mining (Baltz 2008; Fischbach & Walsh 2009; Challis 2008). Doroghazi & 
Metcalf (2013) performed an investigation to determine whether a cryptic biosynthetic gene cluster in 
one species is also likely to be cryptic in a second species. For this they analyzed and compared six 
actinomycete genera (Mycobacterium, Corynebacterium, Rhodococcus, Arthrobacter, Frankia and 
Streptomyces). Their research concluded that the potential to discover novel secondary metabolites is 
still high and especially for the genus Streptomyces the amount of overlapping clusters between 
genomes is very low. Especially strains which are not closely related share no secondary metabolite 
clusters aside from the most common ones (Doroghazi et al. 2014).  
With these findings and the fact that most of these clusters are not expressed under standard laboratory 
conditions, the focus shifts to gain access to this potential. Therefore, new methods have to be 
invented and applied to activate the silent (cryptic) gene clusters. But also known compounds 
previously discovered should be kept in mind because new applications can still be found in new 
screening processes.  
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5. Streptomyces  
 
Figure I.1: Life cycle of Streptomyces. 
The family Streptomyces belongs to the order Actinomycetales. They are immotile, Gram-positive, 
mostly non-pathogenic aerobic soil bacteria with a mycelium-like growth (Stackebrandt & Woese 
1981; Wright & Bibb 1992). The GC-content of their DNA is around 74 %. Streptomyces usually 
contain the LL-form of diaminopimelic acid in their peptidoglycan, their fatty acid pattern consists of 
even-numbered and uneven-numbered fatty acids with a length of 14 to 18 carbon-atoms and they 
usually contain menachinones with nine isoprenic units (Embley & Stackebrandt 1994). Streptomyces 
are able to degrade insoluble organic matter from the soil like cellulose, chitin, lignin or xylanes and 
use them as carbon source. These components are utilized by hydrolysis conferred by exo-enzymes 
like chitinases, ligninases, cellulases, proteases, lipases and nucleases. Streptomyces grow on solid 
media in various different stages of differentiation (Wildermuth 1970; figure I.1). Starting from a 
spore a branched substrate mycelium is formed, which consists of septa, strongly branched hyphae. 
When a lack of nutrients occurs, an aerial mycelium is formed by partial lysis of the substrate 
mycelium. After 3 to 7 days, exospores are formed from the aerial mycelium (Figure I.2). These 
spores are resistant to dryness and other physical stresses.  
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Figure I.2: Spores of Streptomyces sp. Tü 6406 (Diploma thesis Niko Manderscheid). 
About 70 % of all known antibiotics are produced by actinomycetes, whereof Streptomyces form the 
biggest part of the producers (Gräfe 1992). Besides antibiotics, which represent the biggest group of 
bioactive secondary metabolites, also other secondary metabolites produced by Streptomyces show 
biological activities. On the basis of their biological activity secondary metabolites of Streptomyces 
can be classified in 4 groups: (1) inhibitory substances, which include antibacterial, antifungal, 
antiprotozoal and antiviral compounds; (2) pharmacological substances, which include antitumor-
compounds, immunomodulators, neurological substances and enzyme-inhibitors; (3) agricultural 
substances, which include insecticides, pesticides and herbicides; and (4) regulatory substances like 
growth-factors, siderophores and morphogenetic substances (Tarkka & Hampp 2008). 
6. How to access the hidden potential 
New sequencing techniques allow large genomes to be sequenced rapidly and with reasonable costs. 
With the help of analysis tools like antiSMASH (Medema et al. 2011) these genomes can be screened 
quickly and efficiently for secondary metabolite clusters, which leaves us with a huge pool of cryptic 
or poorly expressed gene clusters. The major challenge in the field is therefore to find ways to turn on 
or turn up the expression of cryptic or poorly expressed pathways to provide material for structure 
elucidation and biological testing (Baltz 2011). In his review Baltz (2011) introduced five ways of 
accessing the hidden potential: (1) Disruption of negative regulatory genes; (2) Duplication of 
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secondary metabolite biosynthetic pathway gene clusters; (3) Deletion or disruption of competing 
secondary metabolite pathways; (4) Antibiotic selection for mutations that enhance transcription and 
translation of secondary metabolite genes in stationary phase; (5) Expression of secondary metabolite 
genes in heterologous hosts. Apart from the methods advertised by Baltz (2011), classical methods 
like random mutagenesis with chemical or physical agents or variation of fermentation conditions can 
be used for cluster activation or overproduction. An interesting path to explore is co-cultivation of 
Streptomyces cultures with different bacteria or fungi. Like the studies performed by Schrey et al. 
(2012) or Onaka et al. (2011) assume that microbial communities are very complex and there may be 
substances produced only in close proximity to the corresponding partner. The production of certain 
compounds could also be stimulated by adding extracts of specific organisms to the culture of the 
producing strain of interest (Beauséjour et al. 1999).  
7. Heterologous expression 
Since the natural producers of interesting compounds or strains with cryptic clusters of interest are not 
always genetically accessible, easy to cultivate or show unreliable growth or metabolite production 
profile, heterologous expression of the target genes or clusters is a commonly used tool. The principle 
is to identify genes or clusters of interest and express them in a suitable host using an optimized 
expression system. Thus it is preferred to express these clusters in a well-studied model organism, in 
which a lot of tools were already applied and for which cultivation conditions, media composition and 
storage conditions are well described.  
There are many examples of successful application of this tool. Heterologous expression was used to 
express foreign genes from animals or plants in bacteria or fungi (Frommer & Ninnemann 1995) to 
study gene function or to identify products of gene clusters (Luzhetskyy et al. 2007, Rebets et al. 
2015), to elucidate unknown genes or pathways (Baltz 2010), to engineer known or unknown 
biosynthetic gene clusters (Wenzel et al. 2005), to generate new derivatives of known compounds 
(Luzhetskyy et al. 2007) or to increase the production of desired metabolites (Baltz 2010). 
Despite the huge success of heterologous expression in a vast area of applications, there can be severe 
drawbacks in using this method. Often the yield of the desired product in the heterologous host is 
significantly lower than in the parental strain (Binz et al. 2008; Huo et al. 2012). Steps like the 
introduction of promoters upstream of the cluster to force its expression or the engineering of the 
precursor supply to ensure sufficient production of the desired metabolite have to be made. These 
steps are quite often not intuitive and very time consuming. An additional problem which occurs quite 
often is the toxicity of the produced compound for the heterologous host. To overcome the resistance 
problem, the corresponding resistance genes which are mostly located in close proximity to the gene 
cluster, can be co-expressed. Solutions like these rely heavily on deeper knowledge of the 
corresponding cluster and the produced substance.   
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8. Streptomyces albus J1074 
The S. albus G mutant defective in SalI restriction and modification was labeled S. albus J1074 
(Chater & Wilde 1976). This strain was early on discovered to be a suitable host for cloning and 
expression of streptomycete genes. It was first used as a cloning host by the Salas group (Fernández et 
al. 1996; Ma Rodriguez et al. 1993). S. albus J1074 has since been used for the heterologous 
production of steffimycin (Gullón et al. 2006), fredericamycin (Wendt-Pienkowski et al. 2005; Chen et 
al. 2008), isomigrastatin (Feng et al. 2009) and thiocoraline (Lombó et al. 2006). Since its discovery, 
S. albus J1074 has proven to be a reliable and easy to work with chassis strain for heterologous 
expression of different kinds of gene clusters from various sources and its genome has been 
completely sequenced (Zaburannyi et al. 2014).  
9. Strain development  
Since heterologous expression is a tool of choice for the production of interesting natural products 
from undeveloped natural producer strains, for the increase of production, and a tool for the 
production of compounds from cryptic clusters, suitable heterologous hosts need to be developed.  
Genome sequencing of producers of interesting secondary metabolites revealed the potential of these 
strains to produce not only the known compounds but also several other compounds which are mostly 
cryptic (Bentley et al. 2002; Ikeda et al. 2003; Doroghazi & Metcalf 2013). As a result the idea arose 
to delete all putative secondary metabolite gene clusters to produce a chassis strain for heterologous 
production of secondary metabolites. These strains should produce only the products of the expressed 
clusters and the background noise of naturally produced compounds should be reduced to a minimum. 
This should result in a much clearer spectrum of the produced compounds, which should lead to a 
much easier detection of the heterologously produced substances. With a minimized genome, the flux 
of precursors for biosynthesis should also flow directly into the production of the expressed gene 
cluster and is not divided between several clusters.  
Ikeda et al. (2014) took the industrial producer strain of avermectin, Streptomyces avermitilis, which is 
optimized for precursor supply and is genetically stable, and deleted approximately  
20 % of the genome of S. avermitilis. This deletion mutant did not produce any endogenous 
metabolites but showed no sign of growth limitation, because no essential genes were deleted from the 
chromosome. They showed an increase of production in their minimized strain for streptomycin and 
cephamycin in comparison to the original producers (Komatsu et al. 2010). This proves the genome-
minimized mutant strain to be a versatile and effective host for heterologous expression of secondary 
metabolite clusters. Gomez‐Escribano & Bibb (2011) deleted four endogenous secondary metabolite 
gene clusters from Streptomyces coelicolor M145 and introduced point mutations into rpoB and rpsL 
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to pleiotropically increase the secondary metabolite production. These changes led to an increase 
production of chloramphenicol and congocidine in comparison to the S. coelicolor M145 strain.  
Deletion of disrupting elements such as unwanted secondary metabolite clusters is one possibility to 
increase heterologous production of secondary metabolites. Another possibility is to directly divert the 
precursor production from the primary metabolism to the desired compounds. This can be achieved by 
overexpression of certain genes in order to increase the flux through a certain pathway, as for example 
the overexpression of acetyl-CoA carboxylase leads to an increased rate of fatty acid biosynthesis 
(Davis et al. 2000), by inactivation of certain genes, like the inactivation of the ADP-glucose 
pyrophosphorylase and the acyl-CoA:diacylglycerol acyltransferase led to an increase of the 
intracellular concentration of glucose-1-phosphate / glucose-6-phosphate and thus to an increase in 
mithramycin production (Zabala et al. 2013), or by remodeling or introduction of complete precursor 
pathways, like remodeling of the glycolytic pathway by deletion of two glyceraldehyde-3-phosphate 
dehydrogenases led to an increase in clavulanic acid production (Li & Townsend 2006).  
The deletion of unwanted clusters and the mutations in rpoB and rpsL can be generally beneficial for 
secondary metabolite production, or it can be product specific when the precursor production is 
channeled to enhance the formation of a certain metabolite.  
10. Pamamycin 
Pamamycin is a class of natural products which belong to the macrodiolide antibiotics. Pamamycin-
607 was first discovered in the culture of Streptomyces alboniger ATCC 12461. It is active in vitro 
against Gram-positive bacteria, Neurospora and Mycobacteria (McCann & Pogell 1979). Pamamycin-
607 was shown to be an aerial mycelium-inducing agent (Kondo et al. 1988) and a secondary 
metabolite stimulating substance (Hashimoto et al. 2011). There are at least 14 different kinds of 
pamamycins known. They reach from pamamycin 593 to 649 of which several derivatives share the 
same mass (Natsume et al. 1995; figure I.3).  
 
Figure I.3: Different types of pamamycins (not complete). 
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Pamamycin-607 consists of six acetate, four propionate and three succinate units, and the nitrogen 
atom derives from the α-amino group of an amino acid (Hashimoto et al. 2005a). The final pamamycin 
molecule is assembled from two hydroxyl acids, hereafter referred to as hydroxyl acid large and small, 
with hydroxyl acid small being a stereoisomeric homologue of the building blocks for nonactin 
(Hashimoto et al. 2005b). Nonactin was first discovered in the extracts of a Streptomyces species 
(Corbaz et al. 1955) and belongs to the macrotetrolides group as well. 
11. PKS 
Polyketides are a large family of natural products found in bacteria, fungi and plants, and include 
many clinically important drugs such as tetracycline, daunorubicin, erythromycin, rapamycin and 
lovastatin. They are biosynthesized from acyl CoA precursors by polyketide synthases (Shen 2003). 
There are three types of polyketide synthases known to date. Type I PKS are modular proteins of 
which every module carries out a specific step in the biosynthesis. Type II PKS are commonly 
multienzyme complexes with a set of enzymes which are used iteratively. Type III PKS consist of a 
single enzyme which catalyzes the biosynthesis (Shen & Kwon 2002).  
Type II PKS are of special interest because of the many clinically useful drugs derived from their 
products. PKS II types are mostly iteratively used multienzyme complexes with a minimal PKS 
consisting of the KSα and KSβ subunits and an acetyl carrier protein (ACP). The minimal PKS 
catalyses the iterative decarboxylative condensation of malonyl-CoA extender units with an acyl 
starter unit (Hertweck et al. 2007; figure I.4).  
 
Figure I.4: Basic mechanisms of aromatic polyketide biosynthesis. 
Besides the minimal PKS there are quite often other enzymes in polyketide biosynthesis. The keto 
reductase (KR) catalyzes the stereospecific hydrogen transfer from NAD(P)H onto a keto group, 
resulting in the formation of a secondary alcohol, cyclases support specific ring formation, aromatases 
dehydrate cyclic alcohols to yield aromatic ring systems, methyl transferases transfer the activated 
methyl group from S-adenosyl-L-methionine to nitrogen, carbon or oxygen, oxygenates promote the 
incorporation of oxygen into a substrate, and glycosyltransferases attach sugars to the molecule 
(Hertweck et al. 2007).  
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12. Aim of this work 
The main focus of this work was to engineer Streptomyces albus J1074 for optimized heterologous 
expression of secondary metabolites coupled with the elucidation of the pamamycin biosynthesis and 
optimization of the pamamycin production.  
A cosmid library of Streptomyces alboniger DSM 40043 was created and screened for the pamamycin 
biosynthetic gene cluster. Heterologous expression of the pamamycin biosynthetic genes was 
established in Streptomyces albus J1074 and the biosynthesis was elucidated by knockout of important 
genes and measurement of the resulting intermediates. By knocking out several of the genes 
responsible for precursor supply for pamamycin biosynthesis from the primary metabolism of 
Streptomyces albus J1074, the compound spectrum of produced pamamycins should be shifted into a 
specific direction. Furthermore the bottleneck for pamamycin production in Streptomyces albus J1074 
and the source of precursors should be detected.  
A different approach for an overproduction of secondary metabolites was performed by integration of 
additional page ϕC31 attachment sites into the genome of Streptomyces albus J1074. The effect of 
gene dosage on secondary metabolite production should be shown by the expression of four different 
antibiotic clusters in the panel of produced strains with different amounts of attachment sites.  
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II. Complete genome sequence of         
Streptomyces fulvissimus 
Members of the genus Streptomyces served as a source of new natural products and antibiotics in 
particular for a long time. With the emergence of data indicating that most streptomycetes contain up 
to 30 gene clusters involved in the synthesis of secondary metabolites in their genomes, it has become 
clear that their biosynthetic potential was underestimated (Bentley et al. 2002; Ikeda et al. 2003; 
Ohnishi et al. 2008). Nowadays, lots of efforts are made to estimate this potential and also to get 
access to natural products whose biosynthetic pathways are encoded in the genomes of the 
corresponding Streptomyces strains. Accumulation of high quality genome sequencing data will 
strongly contribute to the implementation of this task. Here we present the complete genome sequence 
of the new Streptomyces strain S. fulvissimus. 
The genome sequencing of S. fulvissimus (DSM 40593) was performed with the Roche GS FLX 
Titanium technology. High molecular mass DNA was extracted from S. fulvissimus and an 8 kb 
paired-end library as well as a shotgun library were constructed. Reads of an approximate length of 
350 bp and 2 x 125 bp were obtained for shotgun and paired-end libraries, respectively. Newbler 
software was used for the genome assembly. Gaps were closed by PCR with subsequent Sanger 
sequencing.  
Annotation was performed by automatically merging 3 annotation sources, with the following manual 
curation and problems resolution. The three sources used were: Glimmer (Delcher et al. 2007) gene 
prediction trained on annotated open reading frames of S. coelicolor and S. avermitilis with BlastP 
annotation against the NR, Nt and swissProt databases; Prodigal (Hyatt et al. 2010) gene prediction 
with AutoFACT (Koski et al. 2005) annotation against UniRef90 and COG; xbase 
(http://xbase.ac.uk/annotation/) annotation against S. coelicolor.  
The S. fulvissimus genome consists of a single linear chromosome of 7,905,758 bp (71,5 % G+C) with 
no plasmids. The chromosome is of smaller size than the ones of S. coelicolor A3(2) (8,7 Mbp),  
S. avermitilis MA-4680 (9,0 Mbp) or S. griseus IFO13350 (8,5 MbP) (Bentley et al. 2002; Ikeda et al. 
2003; Ohnishi et al. 2008). The analysis of the S. fulvissimus genome revealed that its chromosome 
contains 6925 predicted protein coding sequences as well as 73 tRNA genes (Table II.1). Also, similar 
to other streptomycetes like S. coelicolor, S. avermitilis, S. griseus, and S. vattleva etc (Barbe et al. 
2011; Bentley et al. 2002; Ikeda et al. 2003; Ohnishi et al. 2008), the genome of S. fulvissimus 
contains 6 rRNA gene clusters.  
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Table II.1: Genome statistics 
Attribute Value 
Genome size (bp) 7,905,758 
DNA coding region (bp) 7,023,792 
DNA G+C content (bp) 71,5 % 
Number of replicons 1 
Extrachromosomal elements 0 
Total genes 7,027 
rRNA genes 18 
rRNA operons 6 
tRNA genes 73 
Protein coding genes 6,925 
Genes with predicted function 5,194 
Secondary metabolite clusters 32 
 
We estimated the potential of S. fulvissimus to produce secondary metabolites. Preliminary data after 
the analysis of the genome sequence with the secondary metabolites search tool antiSMASH (Medema 
et al. 2011) indicates the presence of 32 putative gene clusters involved in the biosynthesis of different 
natural products (Table II.1). In comparison, genomes of S. griseus and S. avermitilis contain 34 and 
30 secondary metabolite clusters, respectively. Among the clusters of S. fulvissimus, 6 encode NRPS, 
5 are involved in the biosynthesis of terpenoids, 3 encode hybrid NRPS-PKS, 2 are type III PKS, 2 are 
type II PKS, 1 is a type I PKS, 2 are involved in siderophore production and 2 in the biosynthesis of 
lantibiotics. Not surprisingly most of the clusters are located on the terminal arms of the chromosome. 
This data indicates that S. fulvissimus has a high potential to produce secondary metabolites.  
It was described before that S. fulvissimus contains a NRPS gene cluster responsible for the 
biosynthesis of the cyclic depsipeptide ionophore antibiotic Valinomycin (Matter et al. 2009). Its 
structure contains three repeated tetradepsipeptide units of D-a-hydroxyisovaleryl-D-valyl-L-lactyl-L-
valyl (Cheng 2006). Indeed, the genome sequence of S. fulvissimus contains the respective cluster with 
two NRPS genes encoding two modules each. On amino acid level products of these two genes are 
highly homologous to Vlm1 and Vlm2 of S. tsusimaensis ATCC 15141 sharing 84 % and 85 % 
identity, respectively. As in case of S. tsusimaensis, the Valinomycin NRPS genes are flanked by a 
transposase gene and a discrete gene encoding thioesterase (Cheng 2006). 
Furthermore, a cluster homologous to the Nonactin biosynthetic cluster was revealed in the genome 
sequence of S. fulvissimus. Nonactin is a macrotetrolide ionophore antibiotic produced by S. griseus 
DSM40695/ ETH A7796 (Smith et al. 2000; Woo et al. 1999). Both gene organization and nucleotide 
sequence of these clusters are very similar.  
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III. Insights into the pamamycin 
biosynthesis 
1. Introduction 
Pamamycins (1) are a group of macrodiolide antibiotics produced by several Streptomyces species 
(Figures III.1, III.S1). They were identified due to their ability to stimulate formation of aerial mycelia 
in Streptomyces alboniger DSMZ40043 and were demonstrated to inhibit the growth of Gram-positive 
bacteria and fungi (McCann & Pogell 1979; Kondo et al. 1988; Lefevre et al. 2004) . Initially, the 
compound with the structure designated as pamamycin-607 (R1 - R4 = Me, R5 = H) was isolated from 
S. alboniger (Kondo et al. 1988), however, a reexamination of extracts revealed a broader chemical 
diversity of 1 differing in their side chain substituents (Figures III.1, III.S1) (Natsume et al. 1991; 
Natsume et al. 1995; Kozone et al. 1999). 1 are composed of two asymmetrical parts named hydroxy 
acids small (3) and hydroxy acids large (4) (Scheme III.1). Due to the pronounced bioactivities and 
challenging molecular structure, these natural products have stimulated intense synthetic efforts (Metz 
2005; Kang & Lee 2005), which have already culminated in several total syntheses of pamamycin-607 
(Germay et al. 2001; Lee et al. 2001; Wang et al. 2001; Kang et al. 2002) and some homologues 
(Fischer et al. 2005; Ren & Wu 2009; Ren et al. 2010; Fischer et al. 2011). Feeding experiments 
clearly demonstrated the polyketide origin of 1 by the incorporation of 13C labeled acetate, propionate 
and succinate (Hashimoto et al. 2005a). This fact is especially interesting since succinate cannot 
directly participate in Claisen condensation. Respective biochemical reaction as well as the enzyme 
conducting it remained mysterious till now. 
The only other natural products known to utilize succinate as a building block are the macrotetrolide 
antibiotic nonactin (R1 - R4 = Me) (2) produced by S. griseus and S. fulvissimus (Figure III.1) 
(Ashworth et al. 1989; Ashworth & Robinson 1983; Ashworth et al. 1982, 1988; Myronovskyi et al. 
2013). The 2 consist of two enantiomers of tetrahydrofuran rings containing hydroxy acids 
stereospecifically assembled into the final molecule. The gene cluster for the biosynthesis of 2 (non) 
contains 5 ketosynthase KS genes (Kwon et al. 2001; Walczak et al. 2000; Woo et al. 1999). These 
unusual KSs were classified as non-iterative type II PKS based on sequence similarity despite the lack 
of ACP proven by the heterologous expression and deletion experiments (Kwon et al. 2001; Walczak 
et al. 2000). Extensive studies using 13C labeled precursors showed utilization of acetate and succinate 
as building blocks for 2 assembly (Ashworth et al. 1989; Ashworth & Robinson 1983; Ashworth et al. 
1982, 1988) as well as direct incorporation of 3-oxoadipate as a precursor into the 2 (Nelson & 
Priestley 2002), leading to the idea that the first committed step in biosynthesis is condensation of 
succinate and malonate. However, the labeling pattern of 3-oxoadipate used in this study did not  
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Figure III.1: Structures of 1 and 2 and the genetic organization of the respective biosynthesis gene clusters. The origin of 
carbon atoms is color coded: blue – acetate, green – propionate, red – succinate (Hashimoto et al. 2005a; Ashworth et al. 
1989; Ashworth & Robinson 1983; Ashworth et al. 1982, 1988). Arrows indicate decarboxylation. The deduced function of 
genes is based on 2 biosynthesis studies and sequence homology. KS – ketosynthase, AT – acyltransferase, KR/DHO – 
ketoreductase/dehydrogenase, ACP – acyl-carrier protein, AmT – aminotransferase, MT – methyltransferase. 
explain how this intermediate is made by the 2 biosynthesis machinery. Lastly, the acetate 
incorporated in positions of 1 and 2 that correspond to the 3-oxoadipate location proceed through the 
double decarboxylation contributing only one carbon atom to the structure of final molecules. These 
unusual features distinguish the biosynthesis of 1 and 2 from other polyketides. Despite the excellent 
insights into 1 and 2 precursor’s origins, feeding experiments are not sufficient to establish their 
biosynthetic route. Moreover, the non genes inactivation experiments further puzzled the biosynthetic 
hypothesis of macrotetrolides (Kwon et al. 2001; Walczak et al. 2001; Kwon et al. 2002). The aim of 
this project was to elucidate the biosynthetic pathway leading to production of 1 with a focus on the 
enzyme(s) responsible for incorporation of succinate. We endeavor 1) to identify the enzymes capable 
to utilize succinate as an intact four-carbon building block in 1 and 2 biosynthesis; 2) to explain the 
incorporation of only one carbon atom from acetate into polyketide backbone of 1 and 2; 3) to identify 
enzyme(s) responsible for elongation of 3 to 4 by addition of the second succinate unit; 4) to establish 
the entire biosynthetic route leading to assembly of 1. 
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2. Materials and methods 
2.1. Strains, plasmids and culture conditions 
Strains and plasmids used are listed in Table III.S1. E. coli strains were grown in LB with appropriate 
antibiotics as necessary. TSB media was used to grow streptomycetes strains for routine applications. 
MS media was used for genetic manipulations of Streptomyces strains and spore stock preparations 
(Kieser 2000). For pamamycin in production Streptomyces strains were grown in SGG medium 
(Starch soluble 10 g, Glucose 10 g, Glycerol 10 g, Cornsteep Powder 2,5 g, Bacto Peptone 5 g, Yeast 
extract 2 g, NaCl 1 g, CaCO3 3 g, Tap water 1 L, pH 7,3). 
2.2. Preparation and manipulation of DNA 
DNA extraction and manipulation, E. coli transformation and E. coli / Streptomyces conjugation were 
performed according to standard procedures (Kieser 2000; Chong 2001). The hot start KOD DNA 
polymerase (Novagen) was used to amplify fragments used for gene expression. Dream Taq 
polymerase (Fermentas) was used for PCR for the verification of gene deletions in cosmids or 
Streptomyces strains. DNA fragments were purified from agarose gels using the QIAquick Gel 
Extraction Kit (Qiagen). Plasmid and chromosomal DNA were purified with QIAprep Spin miniprep 
kit and DNeasy Blood and Tissue Kit (Qiagen). DNA processing enzymes used in this work were 
obtained from New England Biolabs. Oligonucleotides used in this study are listed in Table III.S2. 
2.3. Sequencing of genomes of S. alboniger DSMZ and  
S. sp. HKI118 and their analysis 
Streptomyces alboniger (DSM40043) was obtained as a lyophilized culture from DSMZ 
(Braunschweig, Germany). Genomic DNA was isolated from 30 mL cultures grown in TSB at 28 °C 
for 24 hours. Total DNA isolation was performed according to the salting out procedure followed by 
RNase treatment (Kieser 2000). Isolated DNA was sent to Baseclear (Leiden, Netherlands) for 
Illumina sequencing. Two libraries were constructed, PE (insert size 250 bp, average total coverage 
225) and MP (insert size 4,000 bp, used only for scaffolding). Assembly of the reads was performed 
with the Mira assembler software version 3.9 (Chevreux et al. 2004) resulting in 330 contigs longer 
than 500 bp. Contigs were reviewed and edited in Gap4 from the Staden package (Staden 1996), 
scaffolded using SSPACE Pro (Baseclear), gaps closed using Soapdenovo GapCloser. The final 
assembly has 7965650 bp (including 1629 Ns) in 10 scaffolds. The longest scaffold has 3,041,941 bp, 
the shortest –5,131 bp, scaffold N50 is 1,406,014. Streptomyces sp. HKI 118 was obtained from 
Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute (Jena, 
Germany) and sequenced by LGC genomics (Berlin, Germany), resulting in 10,817,059 bp in 1,664 
scaffolds. Both genomes were annotated using prokka (Seemann 2014), secondary metabolite clusters 
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were predicted with the help of antiSMASH 2.0 (Blin et al. 2013). To identify pamamycin gene cluster 
1664 scaffolds of Streptomyces sp. HKI 118 were mapped using Geneious (Biomatters Ltd, Auckland, 
New Zealand) to 10 scaffolds of Streptomyces alboniger DSM40043. Sequences of pam clusters from 
both S. alboniger DSM40043 and Streptomyces sp. HKI 118 were deposited in GenBank (accession 
numbers: KM923741 and KM923742). 
2.4. Deletion of the pamD gene in the S. alboniger genome 
Regions flanking pamD gene were amplified using Pmm00734F1Bam/Pmm00734R1EcV (L) and 
Pmm00734F2EcV/Pmm00734R2Xba (R) primer pairs and cloned into pSTBlue-1 AccepTor vector 
(Novagen). The resulting plasmids pSTL and pSTR were digested with BamHI and EcoRV and the 
deletion construct was assembled by cloning the L fragment into pSTR. A spectinomycin resistance 
cassette was cloned into the EcoRV site of the resulting plasmid to give pSTRLaadA. pSTRLaadA 
was digested with BamHI and XbaI and the deletion construct was sub-cloned into pKC1139. The 
final construct was introduced into S. alboniger via intergeneric conjugation. The obtained strain was 
grown in 20 ml of liquid TSB media without antibiotics at 39 °C for 3 days, plated on MS agar 
supplemented with spectinomycin to obtain a single cross-over strain. Plasmid integration was proven 
by resistance marker inheritance after growth for several passages in liquid medium without selective 
antibiotics. After the last cycle in non-selective conditions the strain was plated on MS media and 
spore dilutions were prepared and plated on MS with spectinomycin. The secondary cross-over strains 
were selected by screening for apramycin sensitive and spectinomycin resistant colonies. Seven of 
such colonies have been obtained. The deletion of pamD was proven by PCR analysis. 
2.5. Pamamycin production analysis  
For pamamycin production 2 ml of a 2 day old pre-culture was inoculated into 50 ml of SGG media 
and grown for 3 days at 30 °C with agitation at 250 rpms. The biomass was separated from 
supernatant by centrifugation. Metabolites were extracted with ethyl acetate from cultural liquid and 
with aceton:methanol (1:1) mixture from biomass. Samples were evaporated, dissolved in 200 μl of 
methanol:DMSO (1:1) and subjected to LC-MS analysis. For quantification chemically synthesized 
pamamycin 607 was used as standard. Metabolites were separated on Waters BEH C18 column (100 
mm x 2.1 mm, 1.7 μm, column temperature 45 °C) using an UPLC-ESI-MS instrument (Dionex 
Ultimate 3000, Thermo Fisher Scientific GmbH and amaZon Speed ETD, Bruker). Samples were 
eluted with solvent A: ammonium formate buffer 90 mM and solvent B: 80:20 acetonitrile/100 mM 
ammonium formate buffer in a multistep gradient. 0.2 min 20 % B, 20 % B to 97 %B in 2.8 min, 97 % 
B to 100 % B in 6 min, 2 min 100 % B, 100 % B to 20 % B in 1 min, 3 min equilibration at 20 % B. 
Flow 0.55 mL/min. Alternatively, longer protocol was used with multistep gradient: 0.2 min 10 % B, 
10 % B to 69 % B in 4 min, 69 % B to 87.5 % B in 26 min, 87.5 % B to 95 % B in 0.5 min, 1 min 95 
% B, 100 % B to 10 % B in 0.5 min, 4 min equilibration at 10 % B. Detection for quantitative analysis 
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in srm-mode on Amazon MS-spectrometer using the ms2 fragment m/z = 396 from parent ion of 
Pamamycin m/z =  608 [M+H]+. The reference sample concentrations of Pamamycin 607 were c = 15, 
10, 5, 2.5 and 1 μg/ ml. In the case of extracts from S. albus R2ΔpamX and pamY strains the samples 
were separated on the same UPLC-ESI-MS system with the Waters BEH C18 column (100 mm x 2.1 
mm, 1.7 μm, column temperature 45 °C). 0.1 % formic acid was used as solvent A and 100 
acetonitrile as solvent B. Samples were eluted with gradient of solvent B from 5 to 95 % in 18 
minutes. The flowrate was 0.5 mL/min. 
2.6. Gene library preparation and cloning of the pam-gene cluster 
S. alboniger DSM 40043 chromosomal DNA was purified with the chloroform method (Kieser 2000). 
DNA was partially digested with Sau3A. Digested DNA was size-fragmented by agarose gel. The 27-
39 kb DNA fragments were selected, purified and ligated into pre-cut BamHI and HpaI and CIAP-
treated cosmid pOJ436 vector. Ligation was packaged with package extracts as instructed by the 
SuperCos1 Cosmid Vector Kit (Stratagene). The primary library was titrated on E. coli XL-Blue MRA 
cells. Since the vector has two Cos sites, only colonies containing cosmid plasmid with inserts of 27-
39 kb can be packaged and grown on LB-apramycin plates. Colonies were screened by hybridization 
with the two probes (480 bp each) that correspond to the 5’ and 3’ of the pam gene cluster, 
respectively. The hybridization was performed as described by manufacturer of ECL Direct Nucleic 
Acid Labeling and Detection System (GE Healthcare). Cosmids hybridized with both probes were 
isolated and end sequenced from T7 and T3 primers to prove the cloning of the respective region of 
the S. alboniger chromosome. 
2.7. Construction of the mutant strains 
The cosmids with deletions of the pam gene were constructed using the PCR-based Red/ET 
technology and a hygromycin resistance marker from the iterative markers system (Myronovskyi et al. 
2014a; Zhang et al. 1998). Gene deletions were confirmed by PCR. The mutagenized cosmids were 
introduced into S. albus J1074 by RP4-based conjugation from E. coli ET12567 containing pUZ8002 
and selected for with apramycin (Flett et al. 1997). The hygromycin cassette was removed during 
conjugation due to the activity of the ϕC31 integrase of pOJ436 based cosmid. Integration of cosmids 
into the genome of the recipient strain and loss of the marker were proved by PCR. 
2.8. Complementation of pam gene mutations 
Complementation of strains with a deleted pam gene was performed with pam genes and their 
nonactin counterparts. For this, pam and non genes were amplified using the primers described in table 
III.S2 from genomic DNA of S. alboniger and S. fulvissimus (Myronovskyi et al. 2013) respectively. 
PCR products were digested with HindIII/BamHI or HindIII/BglII and cloned into HindIII/BamHI 
digested pUWLFLPhyg (Fedoryshyn et al. 2008) under control of the ErmE* promoter. Generated 
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plasmids were introduced into S. albus strains containing the respective mutated variants of R2 cosmid 
and selected by hygromycin resistance. Metabolites production was tested as described above. 
2.9. Feeding of mutant strains with hydroxyl acids S and L 
Strains of S. albus R2 with deletions of pamL and pamB genes were grown in SGG media for 2 days 
and mixture of hydroxyl acids S and L mixture was added. Strains were cultivated for two more days, 
metabolites were extracted and production of pamamycins was analyzed as described above. 
2.10. Deletion of 3-oxoadipate:succinyl-CoA transferase gene in  
S. albus J1074 
Genes encoding both subunits of the 3-oxoadipate:succinyl-CoA transferase XNR_0219 and 
XNR_0220 were replaced with a hygromycin resistance cassette within the 1G14 BAC library clone 
using PCR-based Red/ET technology (Zhang et al. 1998; Gust et al. 2004). Recombinant BAC was 
introduced into S. albus J1074 by conjugation and clones were selected with hygromycin. Ten 
colonies were checked for secondary cross-over by PCR and three of them were found to have 
XNR_0219 and XNR_0220 replaced with a hygromycin cassette. 
2.11. Cloning, expression, purification and characterization of 
PamA  
pamA was amplified with the primers 0726ETFNcoI and 0726ETRXhoI using S. alboniger 
chromosomal DNA as a template. The obtained fragment was digested with NcoI and XhoI, and 
inserted into a similarly digested pET28b vector to generate pET28bPamA. pET28bPamA was 
transformed into E. coli BL21(DE3) for overexpression. A flask containing 1.5 L of LB was 
inoculated with overnight BL21 culture containing PamA expression plasmid, and was grown at 37 °C 
until an OD600 of 0.6, followed by a shift to 20 °C. Expression was induced through the addition of 
0.5 mM IPTG. The culture was incubated at 20 °C overnight, and then the cells were harvested by 
centrifugation (5000 x g, 4 °C, 20 min), lysed in lysis buffer (10 mM TrisHCl, pH 7.2; 400 mM NaCl, 
0.1 % Triton X100) containing benzonase nuclease and lysozyme (Novagen). Proteins were purified 
with Ni-NTA agarose (Qiagen), elution buffer replacement and concentration of the protein was done 
using Amicon Ultra spin columns with a cut off at 10 kDa (Merk Millipore). The proteins were 
analyzed by SDS PAGE and stored at -80 °C in 10 % glycerol. The assay was performed in reaction 
buffer containing 10 mM TrisHCl (pH 7.5), 200 mM NaCl, 2 mM MgCl2 and 1 mM DTT in total 
volume of 40 μl. 40 mM of succinyl-CoA and malonyl-CoA (or methyl-malonyl-CoA) were used in 
reaction mixture as substrates. In competition reactions malonyl-CoA and methyl-malonyl-CoA were 
used in concentration 20 mM each or 40 mM of malonyl-CoA and 4 mM of methylmalonyl-CoA. 
Reaction was started by adding 1 mM of purified enzyme. The reaction mixture was incubated for 30 
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min at RT, stopped by adding an equal volume of methanol. 20 μl of the reaction mixture was 
analyzed by HPLC on Dionex Ulitmate 3000 HPLC system using conditions described in (Kaschabek 
et al. 2002). CoA-esters were detected by UV absorption at 260 nm. Fractions containing new peaks 
were collected, evaporated, dissolved in methanol and subjected to HILIC LC-MS analysis on HILIC 
column (Phenomenex Luna 3μ Hilic 200A; 100 x 2.00 mm) using UPLC-ESI-MS system (Dionex 
Ultimate 3000, Thermo Fisher Scientific GmbH and amazon speed, Bruker). As solvent, linear 
gradient of water with 0.1 % ammonium formate (pH4.7) from 95 to 50% against acetonitrile in the 
course of 12 min was used. The flow rate was 0.5 ml/min. 
Table III.S1: Strains and plasmids used in this work. 
Plasmid/Strain Description Source/ reference 
E. coli DH5α General cloning host, supE44 ΔlacU169(φ80lacZΔM15) (Hanahan 1983) 
E. coli BL21 (DE3) expression host Novagen 
E. coli ET12567/ 
pUZ8002 
Host strain for conjugation from E. coli to Streptomyces (Flett et al. 1997) 
E. coli BW25113/ 
pIJ790 
Strain used for λ RED-mediated recombination (Gust et al. 2004) 
S. alboniger DSM 
40043 
S. alboniger wild type strain, 1 producer 
 
(Hesseltine et al. 
1954) 
S. sp. HKI 118 Pamamycin producing strain (Kozone et al. 
2008) 
S. albus J1074 Host for heterologous expression (Zaburannyi et al. 
2014) 
S. alboniger ΔpamD-
7 
DSM40043 derivative with pamD gene replaced by 
spectinomycin resistance cassette, 1 non-producing 
strain 
This study 
S. albus R2 R2 cosmid integrated into J1074 genome This study 
S. albus AdCoA S. albus J1074 derivative with deleted 3-
oxoadipate:succinyl-CoA transferase gene 
This study 
pSTBlue-1 T/A PCR cloning plasmid Novagen 
pET28b Protein expression and purification vector Novagen 
pUWLFLPhyg E. coli-Streptomyces replicative shuttle vector derivative 
of pUWLoriT, Hyg® 
(Fedoryshyn et al. 
2008) 
pKC1139 E. coli-Streptomyces replicative shuttle vector with 
temperature sensitive replicon of pSG5 
(Kieser 2000) 
phyg-OK ApR, HygR; source of hygR6Kγ and oriT for λ RED 
recombination 
(Myronovskyi et 
al. 2014a) 
pKC39pamDLRaadA pKC1139 derivative with construct for pamD 
replacement 
This study 
R2 pOJ436 derivative cosmid containing entire pam gene 
cluster 
This study 
R2ΔpamC R2 derivative with deletion of pamC gene This study 
R2ΔpamG R2 derivative with deletion of pamG gene This study 
R2ΔpamF R2 derivative with deletion of pamF gene This study 
R2ΔpamA R2 derivative with deletion of pamA gene This study 
R2ΔpamB R2 derivative with deletion of pamB gene This study 
R2ΔpamO R2 derivative with deletion of pamO gene This study 
R2ΔpamK R2 derivative with deletion of pamK gene This study 
R2ΔpamJ R2 derivative with deletion of pamJ gene This study 
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Plasmid/Strain Description Source/reference 
R2ΔpamL R2 derivative with deletion of pamL gene This study 
R2ΔpamX R2 derivative with deletion of pamX gene This study 
R2ΔpamY R2 derivative with deletion of pamY gene This study 
pUWLpamC pUWLhyg derivative with pamC gene cloned under 
control of PErmE 
This study 
pUWLlanC pUWLhyg derivative with lanC gene cloned under 
control of PErmE 
This study 
pUWLpamA pUWLhyg derivative with pamA gene cloned under 
control of PErmE 
This study 
pUWLnonU pUWLhyg derivative with nonU gene cloned under 
control of PErmE 
This study 
pUWLpamB pUWLhyg derivative with pamB gene cloned under 
control of PErmE 
This study 
pUWLnonT pUWLhyg derivative with nonT gene cloned under 
control of PErmE 
This study 
pUWLpamJ pUWLhyg derivative with pamJ gene cloned under 
control of PErmE 
This study 
pUWLnonJ pUWLhyg derivative with nonJ gene cloned under 
control of PErmE 
This study 
pUWLpamX pUWLhyg derivative with pamX gene cloned under 
control of PErmE 
This study 
 
Table III.S2: Primers used in this study 
Primer name  Sequence Description 
0729DF CCGACGCAGCGTCCCCCGGAGGAAACGGTGTA
CGAATCGTCGACCCGGTACCGGAGTA 
Deletion of  
pamC 
0729DR CCGTGCGCACCGCGCTCTCCAGGGACCTGGGC
ACGGCTCTGACTACGCCCCCAACTGAGAG 
 
0730DF ATGGACCACAACAGGACACGCGCGGCCGTGCT
GGCGGGCGTCGACCCGGTACCGGAGTA 
Deletion of  
pamG 
0730DR CGCGGTACGTATGCACGGCCAGGGCCGTGACG
TCCGGCCACACTACGCCCCCAACTGAGAG 
 
0731DF ACAGCGGCACGCAACACAGGGAGTCTCATGG
CGCATCAGTCGACCCGGTACCGGAGTA 
Deletion of  
pamF 
0731DR CCATGTCCGCGGGCCTCACGCCTTCCCCAGCA
GGATCGCTGACTACGCCCCCAACTGAGAG 
 
0732DF ATTCCCGGCGGATAGCTTTCCCGTATGGCTGC
ACAGGCTTCGACCCGGTACCGGAGTA 
Deletion of  
pamA 
0732DR GTCCGCGCGGGTTCGGCACCGGTCATGCGGCG
CCGAGTGTGACTACGCCCCCAACTGAGAG 
 
0733DF GGTGCCGAACCCGCGCGGACCGAACCCCTGAA
GGAGACCTCGACCCGGTACCGGAGTA 
Deletion of  
pamB 
0733DR TCACCTGGTGGGATCCTGCGGATCGCGTCACC
TGTAGAATGACTACGCCCCCAACTGAGAG 
 
0737DF GTGAACGGCCATGTCCGATTCCAGGAATGCGC
TGGTGACCTCGACCCGGTACCGGAGTA 
Deletion of  
pamO 
0737DR GGCGTCGTTACGGAACCCAGCCGGGCGGCCCG
CCGCCGTCACTACGCCCCCAACTGAGAG 
 
0738DF GTGAACTACGGCTTTTTCGCGGGGTACTTCGA
GTACCCGCTCGACCCGGTACCGGAGTA 
Deletion of  
pamK 
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Primer name  Sequence Description 
0738DR TCAGATCCGGTACAGGAGGCTGCCCCAGCACC
AGACGCCGACTACGCCCCCAACTGAGAG 
 
0740DF ATGCGGTGACCACGACCAAGGGCCCCCGGGA
CGCACTCGTCGACCCGGTACCGGAGTA 
Deletion of  
pamJ 
0740DR CGGGCCCGGCGCCGGGCGGCGTGTGCTCAGTC
ATCGGTGTGTGTAGGCTGGAGCTGCTTC 
 
0743DF GCCCGGGATCCCTGAATGACGGGCCCCACGAC
GTCAGCGTCGACCCGGTACCGGAGTA 
Deletion of  
pamL 
0743DR GTCACGGGTGACCTCGATCCCGGCCGCCACGC
GGTCCCAACTACGCCCCCAACTGAGAG 
 
0745DF GCCCGGGATCCCTGAATGACGGGCCCCACGAC
GTCAGCGTCGACCCGGTACCGGAGTA 
Deletion of  
pamX 
0745DR GTCACGGGTGACCTCGATCCCGGCCGCCACGC
GGTCCCAACTACGCCCCCAACTGAGAG 
 
0746DF GTGAGTGACGACATGTCCAATGCGCACACCGA
TCGCAAGTCGACCCGGTACCGGAGTA 
Deletion of  
pamY 
0746DR TCACTGCTTGCGGTAGACGGACACCGCGTCCC
TGCTGTCGACTACGCCCCCAACTGAGAG 
 
0729CF CCGGAGGAAACGGTGTACG Verification pamC 
deletion 
0729CR CTCTCCAGGGACCTGGGCA  
0730CF ATGGACCACAACAGGACACG Verification pamG 
deletion 
0730CR GACCGATTCGTACACCGTTT  
0731CF TGTCGACAGCGGCACGCAA Verification pamF 
deletion 
0731CR TGTCCTGTTGTGGTCCATGT  
0732CF GGTACTTCAAGTACCACAGG Verification pamA 
deletion 
0732CR AGGACGATGGTCCGCTCCT  
0733CF TTCGCCATCGGCAGCCAGA Verification pamB 
deletion 
0733CR GCTCCTCACCTGGTGGGAT  
0737CF GTGAACGGCCATGTCCGAT Verification pamO 
deletion 
0737CR GGCGTCGTTACGGAACCCA  
0738CF TATATCACCGGATCGGTCA Verification pamK 
deletion 
0738CR CTTCGCTCAGATCCGGTACA  
0740CF TGTACCGGATCTGAGCGAAG Verification pamJ 
deletion 
0740CR AGGGAGCCCGTTTCGAGCA  
0743CF TTGGTCAACTGGGAGCAGTA Verification pamL 
deletion 
0743CR GGTCACGGGTGACCTCGAT  
0745CF ACAGAACCAGCACGTATCCA Verification pamY 
deletion 
0745CR CATTGGACATGTCGTCACTC  
0746CF GATGACTCGTCAGGGCCAC Verification pamX 
deletion 
0746CR ATGCCTGTACGGGCAGGTT  
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Primer name  Sequence Description 
adCoAtraABDF ATTCGTACGCGCCGAGGAGCTGCCTGCCGTGG
AACGATCCGTCGACCCGGTACCGGAGTA 
Deletion of XNR_0219 
adCoAtraABDR TCAGCGGAGGTAGACCCGGCCCGGGTCGACGT
CCTCGCGCAGCACTACGCCCCCAACTGAGAG 
 
adCoAtraABCF CGTTTCCGATTCGTACGCG Verification XNR_0219 
deletion 
adCoAtraABCR ACGACTCTGATGCGCATGA  
00734F1Bam ATTGGATCCGGGATGCATCTGCACCTGG Deletion of pamD, left 
flanking region 
00734R1EcV ATTGATATCCACCTGTAGAAACCTTGCGG  
00734F2EcV ATTGATATCGCAACACATCGAGTGTGGGA Deletion of pamD, right 
flanking region 
00734R2Xba ATTTCTAGAGTGGAACACGGAGTCGATGA  
0734CheckF TGCGCAGTCTCGATCCGCAA Verification pamD 
deletion 
0734CheckR GTCACCGACGTATTCGGAGA  
0729ComFHind ATAAGCTTGCATACGTACCGCGGCTGA pamC complementation 
of pamC mutation 
0729ComRBam ATGGATCCCCTGACCACAGGAAGCAGC  
lanCFHind ATAAGCTTGATGACGCCACCCACTTCC lanC complementation 
of pamC mutation 
lanCRBam ATGGATCCTCTGTATCTCTTCTCCAGTCT  
0732ComFHind ATAAGCTTATGAGACTCCCTGTGTTGC pamA complementation 
of pamA mutation 
0732ComRBam ATGGATCCGTGCTCATGGTCTCCTTCA  
0733ComFHind ATAAGCTTGCAGCCAGACCTCGGTACT pamB complementation 
of pamB mutation 
0733ComRBam CCTGGTGGGATCCTGCGGAT  
0737ComHind ATAAGCTTTTCCGGTACCAGTGAACGGC pamO complementation 
of pamO mutation 
0737ComBam ATGGATCCGCCGTAGTTCACCCACGGGT  
0738ComHind ATAAGCTTGAATGCCGACGCCACTAGTT pamK complementation 
of pamK mutation 
0738ComBam ATGGATCCTTGGTCGTGGTCACCGCATT  
0740ComFHind ATAAGCTTAGCCTCCTGTACCGGATCT pamJ complementation 
of pamJ mutation 
0740ComRBam ATGGATCCAGGGAGCCCGTTTCGAGCA  
0743ComHind ATAAGCTTCCGGCGGTCACATGGTCGA pamL complementation 
of pamL mutation 
0743ComBgII ATAGATCTCAGACGTCGACGACACGGTG  
0745ComFHind ATAAGCTTACCTCTGGCTGTACGGCAA pamX complementation 
of pamX mutation 
0745ComRBam ATGGATCCCTCACCTTCCATCACGTGGA  
0746ComFHind ATAAGCTTTTCGCCAAGGCCATGGGATG pamY complementation 
of pamY mutation 
0746ComRBam ATGGATCCTACCTACGCCCTGGAAGTAC  
nonKS32FHind ATAAGCTTCCGGAAATCGAGTACTGGCA nonU complementation 
of pamA mutation 
nonKS32RbglII ATAGATCTTTCGGGGGCTGTGGTCATG  
nonATHind    ATAAGCTTGATCGCAGACCTCCGTCAT nonT complementation 
of pamB mutation 
nonATbglII   ATAGATCTTGGTGGTCGTCATCGGTAG  
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Primer name  Sequence Description 
nonOCBam ATAAGCTTATGACCGGCCAGGCCGTCAA NonO complementation 
of pamO mutation 
nonOCHind ATGGATCCAGAAGGTGTCCAGGTCGGTG  
nonNCBam ATAAGCTTCTCCCCGAGAAAGCGGAGAA nonN complementation 
of pamO mutation 
nonNCHind ATGGATCCAAGCCCATCCCGGTGACCAG  
nonKCBam ATAAGCTTTGGGCTCGGGCTGGTACTAC nonK complementation 
of pamK mutation 
nonKCHind ATGGATCCACCGGTCAGAAAGGTGGTCC  
nonJHind ATAAGCTTCAACAGCGCCCTGCTGCT nonJ complementation 
of pamJ mutation 
nonJBam ATGGATCCTGCTGTGAACGTGGGTCAT  
nonLCHind ATAAGCTTTACGAGAGTGTGCTCCAGCT nonL complementation 
of pamL mutation 
nonLCBam ATGGATCCTGGCCCGTCGGAAATGCTTC  
0732ETNcoF ATCCATGGCTGCACAGGCTGAAT Cloning and expression 
of pamA 
0732ETXhoR CTCGAGTGCGGCGCCGAGTGCCAG  
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3. Results and discussion 
To identify the biosynthetic genes for 1, the genomes of two producing strains, S. alboniger 
DSMZ40043 and S. sp. HKI 118, were sequenced, searched for secondary metabolism gene clusters 
with AntiSMASH (Blin et al. 2013) and aligned to identify clusters present in both strains. Only two 
regions coding for PKS and terpenoid biosynthesis were identical in S. alboniger and S. sp. HKI118. 
The PKS gene cluster from the S. alboniger contains 20 genes with counterparts in the S. sp HKI118 
and share a high degree of homology with the non clusters of S. fulvissimus (Myronovskyi et al. 2013) 
and S. griseus subsp. griseus (Kwon et al. 2001; Walczak et al. 2000; Woo et al. 1999) (Figure III.1, 
Table III.S3). This cluster (pam-cluster) consists of two “cores” of KS genes. The “right core” highly 
resembles the non gene clusters and includes 5 KS (pamA,D,E,K,J), 3 KR/DHO (pamO,M,N), AT 
(pamB), nonS-like enoyl-CoA hydratase (pamS, putatively involved in tetrahydrofuran ring closure) 
(Woo et al. 1999), acyl-CoA ligase (pamL) and putative resistance (pamH) genes (Figure III.1). In 
addition, genes for an aminotransferase (AmT) and a methyltransferase (MT) (pamX and Y) are located 
in this part of the cluster. The “left core” includes two KS (pamF and G) and ACP (pamC) genes. 
Genes encoding a putative transporter protein and two transcriptional regulators of the TetR and LuxR 
families were also found flanking the biosynthetic genes. All KS in the cluster, except for PamA, 
possess characteristic CHN active site triad with N predicted as acyl-CoA binding site (Table III.S4). 
This architecture of catalytic residues is more typical for type III PKS enzymes rather than for type II 
where CHH motif is conserved (van Lanen & Shen 2008). 
The pamD gene, encoding a KS from the “right core” of the cluster (Figure III.1), was deleted from 
the chromosome of S. alboniger. This mutant failed to produce 1, proving that the identified region is 
indeed responsible for its biosynthesis (Figure III.S2). An S. alboniger cosmid library was created and 
screened for clones containing the entire set of pam genes using two probes flanking the cluster. 
Expression of one of the positive clones, termed R2, in S. albus J1074 resulted in the production of 1 
(Figure III.S3). 
To determine the sequential biosynthetic steps resulting in 1 production, a set of mutant cosmids with 
deletions of individual pam genes was created. Metabolites produced by recombinant S. albus strains 
harboring these cosmids were analyzed by LC-MS (Table III.1). In contrast to the deletions of pamB, 
pamD and pamO, which led to the complete cessation of biosynthesis, S. albus containing cosmids 
with mutations in pamK, pamJ and pamL retained the ability to produce 3 and 4 (Table III.1, Figure 
III.S4). This indicates that PamB, D and O are responsible for the initial steps of 1 biosynthesis, which 
are shared for both 3 and 4, while PamK, PamJ and PamL are involved in the final steps of 1 
formation. Deletion of aminotransferase and methyltransferase genes pamX and pamY resulted in 
accumulation of 3 and hydroxy acid K (5) (Table III.1, Figure III.S5) (Hashimoto et al. 2005b), the 
non-aminated precursor of 4. This proves that amination and methylation occur before the closure of 
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the macrodiolide ring as proposed previously (Hashimoto et al. 2005b). In contrast, deletion of the KS 
genes pamF and pamG from the “left core” of the cluster caused accumulation of 3, whereas neither 1 
nor 4 were found, indicating that these enzymes are necessary for the extension of 3 to give 4. 
Deletion of pamC, which encodes ACP, perturbed the structural range of 1, with a shift toward 
accumulation of lower molecular weight compounds (Table III.1, Figure III.S6). This result indicates 
that PamC participates in the delivery of starter units as described in several cases of bacterial type III 
PKS (Song et al. 2006). 
Table III.1: Accumulation of 1 and their precursors produced by S. albus strains harboring cosmids with various pam gene 
deletions. 
Cosmid\Compound 1 3 4 5 
R2 + + + - 
pamC [a] + + + - 
pamG - + - - 
pamF - + - - 
pamA [a] + + + - 
pamB - - - - 
pamD - - - - 
pamO - - - - 
pamK - + + - 
pamJ - + + - 
pamL - + + - 
pamX - + - + 
pamY - + - + 
 
Deletion of pamA caused a significant decrease in 1 production as well as changes in the structural 
range of accumulated compounds (Table III.1, Figure III.S7, II.S8). Because PamA was proposed to 
participate in the first condensation step of the pathway, any perturbation of its function should lead to 
the complete cessation of 1 production. PamA catalyzed condensation of succinate and malonate 
should result in the production of 3-oxoadipyl-CoA that is one of the key intermediates in the 
degradation of aromatic compounds in bacteria (Díaz et al. 2013). A KEGG COMPOUND search 
(Hattori et al. 2003) of the S. albus genome revealed genes that could cause accumulation of this 
metabolite including the gene for 3-oxoadipate:succinyl-CoA transferase. Thus, in the absence of 
PamA, the biosynthesis machinery for 1 draws 3-oxoadipyl-CoA from the primary metabolism 
resulting in the residual accumulation of 1. S. albus lacking the 3-oxoadipate:succinyl-CoA transferase 
gene was generated. This mutant remained able to produce 1 when the pamA deficient cosmid was 
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introduced (Figure III.S8). However, the level of production was severely reduced. Thus, 3-oxoadipyl-
CoA is an intersection point for primary metabolism and the 1 biosynthesis pathway. The fact that the 
mutant strain was still able to produce 1 indicates existence of an alternative mechanism of 3-
oxoadipate production via a 3-oxoadipate:succinyl-CoA transferase independent process, most likely 
through the phenylacetic acid degradation pathway (Díaz et al. 2013). 
 
 
Figure III.2: HPLC profiles of CoA-esters standards and reaction mixtures containing PamA protein. A. CoA-SH, B. 
Malonyl-CoA, C. Succinyl-CoA, D. Reaction mixture with heat-inactivated PamA. E. Reaction mixture with PamA. F. 
Methylmalonyl-CoA. G. Reaction mixture with PamA and malonyl-CoA substituted with methylmalonyl-CoA. AdC - 3-
oxoadipyl-CoA, MAdC - 2-methyl-3-oxoadipyl-CoA. 
The function of PamA in pamamycin biosynthesis was further demonstrated by in vitro reconstitution. 
PamA was overexpressed in E. coli and purified (Figure III.S9). The enzyme’s activity was tested in 
an assay containing malonyl-CoA and succinyl-CoA. The reaction was monitored by HPLC (Figure 
III.2). Fractions corresponding to the detected peaks were collected and subjected to LC-MS analysis 
using an HILIC approach (Jandera 2011). Formation of a new compound with an HPLC retention time 
(RT) of 16.2 min and an absorption spectrum typical of CoA-esters was observed in the reaction 
mixture after 30 min of incubation (Figure III.2E), and the amount of this compound was further 
increased with increasing the reaction time. HILIC-LC- MS analysis of this product yielded an m/z of 
909.6, which corresponds to the mass of 3-oxoadipyl-CoA (calculated m/z: 909.61) (Figure III.2, 
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III.S10). The side chains R2 and R5 in several 1 contain methyl groups (Figure III.1) that are predicted 
to be incorporated by the PamA reaction, suggesting enzyme-substrate promiscuity. 
 
Scheme III.1: Proposed pathway for the biosynthesis of 1.  
Accordingly, PamA incubated with succinyl-CoA and methylmalonyl-CoA instead of malonyl-CoA 
produced a new compound with an RT of 17.1 min and an m/z of 924. (Figure III.2, III.S11). This m/z 
corresponds to the predicted mass of 2-methyl-3-oxoadipyl-CoA (calculated m/z: 924.64). When the 
reaction was performed in the presence of both malonyl- and methylmalonyl-CoA substrates, the ratio 
of the products was found to depend on the initial ratio of the substrates (Figure III.S12). Thus, unlike 
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NonU, which appears to be specific to malonate because no version of 2 with side chains substituents 
is known, PamA is more flexible in its choice of substrates. Furthermore, introduction of nonU into 
the pamA mutant strain did not restore the native range of 1 produced, due to NonU inability to 
produce 2-methyl-3-oxoadipate (Table III.S5). The ability of NonU to synthesize 3-oxoadipyl-CoA is 
masked by its supply from the primary metabolism. 
Using obtained genetic and biochemical data the entire pathway leading to the formation of 1 was 
proposed (Scheme III.1). The first pathway reaction is the PamA-catalyzed condensation of succinyl-
CoA with malonyl- or methylmalonyl-CoA. The resulting compounds are then rotated by PamB 
acyltransferase as proposed by Rong and co-authors (Rong et al. 2010). The resulting 4-oxoadipyl-
CoA and 5-methyl-4-oxoadipyl-CoA are key intermediates in the biosynthetic pathway for 1 and are 
used as extenders for a Claisen condensation facilitating the incorporation of succinate. PamD 
catalyzes the first extension of a short chain acyl starter unit with one of these compounds followed by 
the PamE-catalyzed addition of malonyl-CoA. The starter units are most likely supplied as ACP-esters 
(Song et al. 2006). After this step, the biosynthetic pathway divides into two branches. In one, the 
activity of the KRs PamO, M and N coupled with the closure of the tetrahydrofuran ring by PamS, 
results in the formation of 3. In the other branch, PamF adds the second molecule of adipate followed 
by the final extension with malonate catalyzed by PamG. Ketoreduction and closure of the 
tetrahydrofuran rings by PamO, M, N and S result in the formation of 5, which is further reductively 
aminated and methylated by PamX and PamY, respectively, to produce 4. Both 3 and 4 are re-
activated by PamL, an acyl-CoA ligase. The feeding of free acids mixture to the S. albus culture 
expressing the pamL, pamJ and K genes produced 1 (Figure III.S13). The closure of the 1 
macrodiolide ring is performed by PamJ and PamK KSs, which catalyze an unusual C-O condensation 
reaction (Kwon et al. 2002). 
III. Insights into the pamamycin biosynthesis 
 
 
30 
 
4. Conclusion 
In summary, the biosynthetic gene cluster for the unusual polyketide secondary metabolite 1 was 
cloned, and the steps leading to its production were elucidated. In particular, the mechanism of 
succinate incorporation into the polyketide backbone was demonstrated to occur through 3-oxoadipyl-
CoA, which represents a new node intermediate between the secondary and primary metabolism. To 
the best of our knowledge, PamA is the first studied enzyme responsible for the incorporation of 
succinate into a polyketide molecule. The same condensation reaction occurs in the biosynthesis of the 
2 and macrodiolide compound that consists of two molecules of homononactic acid (Jois et al. 1986). 
The biosynthetic genes responsible for the production of the latter compound may be early 
predecessors of the pam and non gene clusters. The biosynthesis of these compounds is an interesting 
example of the utilizing of unusual substrates to increase the structural diversity of polyketide natural 
products. In addition, the characterized pam genes will greatly expand the toolbox for combinatorial 
biosynthesis of new polyketides. 
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IV. Strain development of Streptomyces 
albus J1074 for pamamycin production 
1. Introduction 
Pamamycin is a macrodiolide antibiotic of polyketide origin. Its biosynthesis utilizes several building 
blocks from the primary metabolism including succinyl-CoA, malonyl-CoA, methylmalonyl-CoA, 
ethylmalonyl-CoA and 3-oxoadipyl-CoA (Rebets et al. 2015). The ketoacyl synthases act 
promiscuously and incorporate building blocks based on their abundance. This leads to a variety of 
different compounds of which 14 have already been described (Natsume et al. 1995; figure IV.1).  
 
Figure IV.1: Different types of pamamycins (not complete). 
 
Figure IV.2: HPLC-MS chromatogram of a S. albus J1074 / R2 extract. Different types of pamamycins marked by their 
corresponding m/z. 
Many different compounds produced by a single biosynthetic cluster lead to a complex HPLC-profile 
as shown in figure IV.2. This does not only result in difficulties in the analysis of the spectra but also 
leads to more pressuring problems like overall production yields for single compounds and problems 
in purification of specific products. 
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Since different pamamycins are a result of the incorporation pattern of the utilized building blocks, the 
hypothesis is that the compound spectrum could be heavily influenced by manipulation of the building 
block production levels.  
All utilized building blocks are products of the primary metabolism of the producer strain and are 
either intermediates in energy generation and precursor supply like succinyl-CoA, intermediates of 
degradation processes like 3-oxoadipyl-CoA (Díaz et al. 2013), or building blocks for cellular 
structures like malonyl-CoA, methylmalonyl-CoA or ethylmalonyl-CoA. The biosynthetic pathways 
to these compounds are well studied (Chan et al. 2009) and they are thus excellent targets for 
manipulation. 
Pamamycin biosynthetic studies revealed succinyl-CoA and 3-oxoadipyl-CoA as the essential building 
blocks, which leaves malonyl-CoA, methylmalonyl-CoA and ethylmalonyl-CoA prone to 
manipulation.  
Extender units like malonyl-CoA, methylmalonyl-CoA and ethylmalonyl-CoA are common for 
polyketide biosynthesis. Malonyl-CoA is incorporated into the type I PKS associated compounds e.g. 
lovastatin (Kennedy et al. 1999; Ma & Tang 2007), into type II PKS associated compounds e.g. 
daunorubicin, doxorubicin and griseorhodin (Strohl et al. 1997; Otten et al. 1990; Li & Piel 2002) and 
into the type III PKS associated compounds e.g. 3,5-dihydroxyphenylglycine (Chen et al. 2001). 
Methylmalonyl-CoA is most often incorporated into the type I PKS associated compounds e.g. 
erythromycin (Rawlings 2001) and rarely into the type II associated compound e.g. nonactin 
(Ashworth et al. 1989). PKS I derived compounds incorporating ethylmalonyl-CoA include 
compounds like monensin A (Le Day et al. 1973), elaiophylin (Gerlitz et al. 1992), concanamycin 
(Bindseil & Zeeck 1994), tylosin (Omura et al. 1977), leptomycin B (Hamamoto et al. 1985) and 
spiramycin (Inoue et al. 1983).  
Malonyl-CoA and methylmalonyl-CoA derive from the primary metabolism and are mainly used for 
fatty acid biosynthesis, macrolide and polyether antibiotic formation (Zhang et al. 1999). Straight-
chain and branched-chain fatty acids of streptomycetes are formed from the catabolism of L-valine, L-
isoleucine and L-leucine (Massey et al. 1976; Wallace et al. 1995). Malonyl-CoA can either be used 
for branched-chain fatty acids (Kaneda 1991) or for n-fatty acids in mycobacteria whereas 
methylmalonyl-CoA is used for branched-chain fatty acids in mycobacteria (Kolattukudy et al. 1997).  
Ethylmalonyl-CoA is an intermediate in the ethylmalonyl-CoA pathway used for acetyl-CoA 
assimilation and hereby provision of cell constituents in bacteria that lack isocitrate lyase activity (Erb 
et al. 2007). Isocitrate lyase is a key enzyme in the glyoxylate cycle. The crotonyl-CoA carboxylase / 
reductase (CCR) which forms ethylmalonyl-CoA by carboxylation of crotonyl-CoA is not only used 
by bacteria lacking the isocitrate lyase but also in bacteria like streptomycetes to supply extender units 
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for polyketide biosynthesis (Quade et al. 2012; Wilson & Moore 2012; Alber 2011; Liu & Reynolds 
2001).  
The starter unit succinyl-CoA is very rare and is only found in one other compound class besides 
pamamycin which is nonactin (Nelson & Priestley 2002) shown in figure IV.3. In fact, pamamycin 
and nonactin biosynthesis have very similar gene clusters (figure IV.4), with nonactin having one 
additional ketoreductase / dehydrogenase gene and pamamycin having two additional ketosynthase 
genes respectively (Rebets et al. 2015).  
 
Figure IV.3: Structures of pamamycin (1) and nonactin (2). The origin of carbon atoms is color coded: blue–acetate, green–
propionate, red–succinate. Arrows indicate decarboxylation (Rebets et al. 2015). 
 
Figure IV.4: Genetic orientation of the pamamycin and nonactin gene clusters. KS: ketosynthase, AT: acyltransferase, 
KR/DHO: ketoreductase/dehydrogenase, ACP: acyl-carrier protein, AmT: aminotransferase, MT: methyltransferase (Rebets 
et al. 2015). 
The knowledge of the promiscuity of the ketosynthases in pamamycin biosynthesis and their many 
different derivatives led to the idea to simplify the compound spectrum by tuning the precursor supply.  
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Ethylmalonyl-CoA is incorporated into all pamamycins bigger than pamamycin 621 and in several 
derivatives of pamamycin 607 and 621. Methylmalonyl-CoA is incorporated into all known 
derivatives of pamamycin.  
It was hypothesized that a knockout of the ethylmalonyl-CoA producing genes should lead to a 
decrease or disappearance of the pamamycins bigger than pamamycin 621 and of several derivatives 
of pamamycin 607 and 621. This should lead to a simplified compound spectrum and an increase in 
production of the remaining pamamycins. Knockout of the genes responsible for methylmalonyl-CoA 
production should either completely abolish pamamycin production or reveal the presence of small 
pamamycins without methylmalonyl-CoA. 
A panel of several different combinations of the knocked out genes with the final mutant lacking all of 
the identified genes was created and the pamamycin cosmid with the biosynthetic gene cluster was 
brought into these strains and pamamycin production was measured. 
  
IV. Strain development of Streptomyces albus J1074 for pamamycin production 
 
 
35 
 
2. Materials and Methods 
2.1. Materials 
2.1.1. Equipment 
Table IV.1: Devices used in this work 
Device Identifier Manufacturer 
Biological Safety 
Cabinet 
NU-437-600E Nuaire, Plymouth, USA 
Centrifuges Centrifuge 517R 
MF 48-R 
 
Micro Centrifuge AL 220VAC 
MiniStar silverline 
Eppendorf, Hamburg 
Awel centrifugation, BLAIN, 
France 
Carl Roth, Karlsruhe 
VWR, Erlangen 
Electroporator Eporator Eppendorf, Hamburg 
Gel documentation  
system  
Gel Stick “Touch” INTAS, Göttingen 
Gel elektrophoresis-
equipment 
Elektrophoresis chamber MIDI 1  
Power Supply EV 261 
CarlRoth, Karlsruhe            
Consort, Turnhout, Belgium 
HPLC-System Dionex Ultimate 3000 
 
ESI-MS amazon 
Thermo Fischer Scietific, 
Braunschweig 
Bruker, Billerica, USA 
Incubators Heraeus Function line  
 
Infors HT Multitron Standard 
Thermo Fischer Scientific, 
Braunschweig 
Infors, Einsbach 
Magnet stirrer Heat-stir CB162 Stuart, Staffordshire, UK 
pH-meter MP230 Mettler Toledo, Columbus, 
USA 
Photometer BioPhotometer plus Eppendorf, Hamburg 
Pipets Pipetman 0,2 – 2 µl, 1 – 10 µl,  
2 – 20 µl, 20 – 100 µl, 50 – 200 µl,  
200 – 1000 µl 
Gilson, Villiers le Bel 
 
Plate reader POLARstar Omega BMG labtech, Ortenberg 
Sample concentrator Dri-Bock heater DB-3, 25 - 100 °C 
Sample concentrator SC-400 
Biostep, Burkhardtsdorf 
Scales M-power 
Practum® Analysenwaage PRACTUM 
124-1S 
Sartorius, Göttingen 
Thermocycler peqSTAR 2x Gradient VWR, Erlangen 
Thermomixer Thermomixer F 1.5 Eppendorf, Hamburg 
Ultrapure water  MilliQ Water Purification System Millipore, Schwalbach 
Vortex Vortex-Genie 2 Scientific Industries, New 
York, USA 
Water bath WnB1 Waterbath Memmert, Schwabach 
 
 
 
IV. Strain development of Streptomyces albus J1074 for pamamycin production 
 
 
36 
 
2.1.2. Consumables  
Table IV.2: Consumables used in this work 
Description Manufacturer 
Disposable cuvettes 1,5 ml Brand, Wertheim 
HPLC-vials TopSertTPX neoLab, Heidelberg  
Microtube 1,5 ml Sarstedt, Nümbrecht 
Multi-Pro PCR tubes Sarstedt, Nümbrecht 
Parafilm American National Can, Chicago 
Petri dishes 94/16 mm  Greiner bio-one, Frickenhausen 
Pipet tips Sarstedt, Nümbrecht 
Rotilabo-syringe filter CME  Carl Roth, Karlsruhe 
Safe seal microtube 2 ml Sarstedt, Nümbrecht 
Syringe Omnifix 10 ml B. Braun, Melsungen  
Tube 15ml, 50 ml Greiner bio-one, Frickenhausen 
 
2.1.3. Chemicals 
If not specifically mentioned, all used chemicals were p.a. from Sigma-Aldrich Chemie, Steinheim.   
Table IV.3: Chemicals used in this work 
Chemicals Manufacturer 
6X DNA loading dye Fischer Scientific, Schwerte 
Acetone Fischer Scientific, Schwerte 
Agarose, molecular grade  Bioline, Luckenwalde 
Ampicillin sodium salt Carl Roth, Karlsruhe 
Bacto Casaminoacids Difco Laboratories, Augsburg 
Bacto Peptone Difco Laboratories, Augsburg 
CaCl2 VWR, Erlangen 
CaCO3 Carl Roth, Karlsruhe 
CaCO3 Carl Roth, Karlsruhe 
CH3COOK Carl Roth, Karlsruhe 
Chloramphenicol  Carl Roth, Karlsruhe 
dNTPs (100 mM) Fischer Scientific, Schwerte 
Ethylacetate Fischer Scientific, Schwerte 
GeneRulerTM 1 kb DNA Ladder  Fischer Scientific, Schwerte 
Glacial acetic acid Merck, Darmstadt 
Glycerol VWR, Erlangen 
HCl Carl Roth, Karlsruhe 
Hygromycin B Carl Roth, Karlsruhe 
Kanamycin sulfate Carl Roth, Karlsruhe 
Lincomycin Alfa Aesar, Karlsruhe 
L-rhamnose Carl Roth, Karlsruhe 
Maltose monohydrate Carl Roth, Karlsruhe 
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Chemicals Manufacturer 
Methanol  Fischer Scientific, Schwerte  
MgCl2 VWR, Erlangen 
NaCl VWR, Erlangen 
Nalidixic acid Carl Roth, Karlsruhe 
NaOH Carl Roth, Karlsruhe 
Oatmeal (Holo Hafergold) Neuform, Zarretin 
Polypeptone Carl Roth, Karlsruhe 
SDS Carl Roth, Karlsruhe 
Soymeal fat-reduced / fat Henselwerk, Magstadt Sobo Naturkost, Köln-
Marsdorf Spielberg, Brackenheim 
Starch soluble Carl Roth, Karlsruhe 
 
2.1.4. Cultivation Media 
pH was adjusted accordingly with HCl or NaOH. All media were autoclaved for 20 minutes at 120 °C. 
1.5 % Agar was added prior to autoclaving to solid media unless stated otherwise.  
Table IV.4: Cultivation media used in this work 
Description Composition  
LB (Sambrook et al. 1989) NaCl 
Yeast extract 
Tryptone 
deionized water 
5 g 
5 g 
10 g 
ad 1.0 l 
MS (Kieser 2000) Mannitol 
Soymeal fat  
Agar 
deionized water 
20 g 
20 g 
20 g 
ad 1.0 l 
NL 410 (pH 7,0) Glucose 
Glycerol 
Oatmeal 
Soymeal 
Yeast extract 
Bacto Casaminoacids 
CaCO3 
Tap water 
10 g 
10 g 
5 g 
10 g 
5 g 
5 g 
1 g 
ad 1.0 l 
NL SGG (pH 7,3) Starch soluble 
Glucose 
Glycerol 
Cornsteep Powder 
Bacto Peptone 
Yeast extract 
NaCl 
CaCO3 
Tap water 
10 g 
10 g 
10 g 
2,5 g 
5 g 
2 g 
1 g 
3 g 
ad 1.0 l 
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Description Composition  
PPM (Hashimoto et al. 2005a) Maltose monohydrate 
Polypeptone 
Yeast extract 
NaCl 
CaCO3 
deionized water 
15 g 
10 g 
3 g 
3 g 
2 g 
ad 1.0 l 
 
2.1.5. Solutions and buffers 
Table IV.5: Solutions and buffers used in this work 
Description Composition   
Agarose in 1 x TAE-Puffer 1% 
TAE-buffer (50 x) Tris/HCl (pH 7,6) 
EDTA 
Glacial acetic acid 
deionized water 
242.2 g 
18.62 g 
57.1 ml 
ad 1.0 l 
Ethidiumbromide (1 % w/v) 
for staining 
 5 µg/ml in 1 l 
deionized water 
Conservation solution Glycerol 
Sucrose  
deionized water 
(autoclave) 
20 g 
10 g 
ad 70 ml 
 
 
TE-Puffer (pH 8,0) 1 M Tris 
0.5 M EDTA 
deionized water 
12.5 ml 
25 ml 
ad 500 ml 
Buffer 1 (Plasmid isolation) 
 
1 M Tris-HCl 
0.5 M EDTA 
deionized water 
12.5 ml 
10 ml 
ad 500 ml 
Buffer 2 (Plasmid isolation) 10 % SDS 
1 N NaOH 
deionized water 
50 ml 
100 ml 
ad 500 ml 
Buffer 3 (Plasmid isolation) 5 M CH3COOK 
glacial acetic acid 
deionized water  
300 ml 
57.5 ml 
500 ml 
Buffer 1 (MaxBac kit) 1 M glucose 
1 M Tris (pH 8) 
0.5 M EDTA 
deionized water 
10 ml 
5 ml 
4 ml 
ad 200 ml 
Buffer 2 (MaxBac kit) 10 % SDS 
1 M NaOH 
deionized water 
20 ml 
40 ml 
ad 200 ml 
Buffer 3 (MaxBac kit) CH3COOK 
glacial acetic acid 
deionized water 
58.8 g 
23 ml 
ad 200 ml 
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2.1.6. Enzymes and kits 
As long, as not stated otherwise, all enzymes used in this work were from Fischer Scientific, Schwerte. 
Table IV.6: Enzymes and kits used in this work 
Enzyme or Kit Manufacturer 
Lysozyme Carl Roth, Karlsruhe 
Wizard ® SV Gel and PCR Clean-Up System Promega, Madison, USA 
Pure Yield ™ Plasmid Midiprep System Promega, Madison, USA 
Wizard ® Plus SV Minipreps DNA Purification System Promega, Madison, USA 
BACMAX ™ DNA Purification Kit Epicentre, Madison, USA 
 
2.1.7. Antibiotic solutions 
All antibiotic stock solutions were stored at – 20 °C. 
Table IV.7: Antibiotics with stock solution and working concentration used in this work 
Antibiotic Solvent Stock 
solution 
Working 
concentration 
Target 
Ampicillin H2O 100 mg/ml 100 µg/ml E. coli 
Apramycin H2O 100 mg/ml 50 µg/ml E. coli / Streptomyces 
Chloramphenicol Ethanol 25 mg/ml 50 µg/ml E. coli 
Hygromycin H2O 50 mg/ml 100 µg/ml E. coli / Streptomyces 
Kanamycin H2O 30 mg/ml 50 µg/ml E. coli 
Nalidixic Acid 1 N NaOH 100 mg/ml 50 µg/ml E. coli 
Lincomycin H2O 100 mg/ml 100 µg/ml Streptomyces 
 
2.1.8. Synthetic oligonucleotides 
Oligonucleotides used in this work were synthesized by Eurofins Genomics, Ebersberg. Concentration 
of the primers in the PCR reaction was 10 µM.  
Table IV.8: Primers used in this work 
Primer name Primer sequence (5’  3’) 
ccr1SalChckF TCAGCCCTCACTACGCCCTT 
ccr1SalCheckR TTCTGGCGCTCTGTCATGGA 
ccr1SalDF CACTACGCCCTTCGCCGGAGGCACCACCGTGAAGGAAATATTCCG
GGGATCCGTCGACC 
ccr1SalDR TGGCGCTCTGTCATGGAGGGAACCTCAGATGTTCCGGAATGTGTA
GGCTGGAGCTGCTTC 
MCM_redET_for CCGTCAGCGGCTCACAGCTCGTGGCCGAGCGACGCGGCAAGCCGC
TCGACTTCCGGGGATCCGTCGACCC 
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Primer name Primer sequence (5’  3’) 
MCM_redET_rev GGGCAAGGTCACAGGCGCGGGTACTGCTGCACGCCTGCCGCGCTG
TCCTATGTAGGCTGGAGCTGCTTCG 
MCM_seq_for GATCGATCGTCGCCGCCAT 
MCM_seq_rev ATCAGCAGCGTTGCGGAGA 
PCC1_redET_for TCATGCCTGGGCCTCCTCGGCGGGGGTGGCGGGAGCCTGCCGTAC
GACGGTTCCGGGGATCCGTCGACCC 
PCC1_redET_rev TCATTAACGCCGGAGCGGTCGCCCCACCGGAGGCCGCGCCGGTCA
CGGCATGTAGGCTGGAGCTGCTTCG 
PCC1_seq_for GTGGCGGGGGTGGGTGATT 
PCC1_seq_rev GGTCGTTAGCGGTCGTTAA 
PCC2_redET_for GGCTGCGCGCCCGCCACCTCGACATCCCCGAAGCCGTCCTCAGCC
AGGAGTTCCGGGGATCCGTCGACCC 
PCC2_redET_rev TCACGCGGTTTCCTCCTGGACGACGGCGAGCAGGGCACCGACCTC
GACCTTGTAGGCTGGAGCTGCTTCG 
PCC2_seq_for ATCAGGGTGGTGGCGGTGG 
PCC2_seq_rev CTGCTCGGTGACGGTGTCG 
VDH_redET_for CACCTTTACGGACTCCGCCCATCCGCCGCATCTCACCGGGAGTCAC
CACCTTCCGGGGATCCGTCGACCC 
VDH_redET_rev CGGCGACGGGGGAAAATTGGCCGGAAATGATCCTCCGTCCGGGGT
GCGGGTGTAGGCTGGAGCTGCTTCG 
VDH_seq_for CTCATGCCACGGCGTCCGC 
VDH_seq_rev AATCCCCCGCCGCACACCT 
 
2.1.9. Plasmids and Cosmids  
Table IV.9: Plasmids and Cosmids used in this work. 
Name Marker Description 
patt-saac-OriT aac(3)IV Plasmid containing the IMES 
(Myronovskyi et al. 2014a), used for gene 
replacement by redET  
pR2 Aac(3)IV Cosmid containing the pamamycin gene 
cluster (Rebets et al. 2015). 
pSMARTgus cat Cosmid used for S. albus J1074 BAC 
library, containing the GUS gene 
pSMARTgus_1M11 cat Cosmid containing the genomic regions of 
the PCC 2 gene 
pSMARTgus_1M11_ΔPCC 2 cat/ aac(3)IV PCC 2 gene replaced with IMES 
pSMARTgus_2E5 cat Cosmid containing the genomic regions of 
the PCC 1 gene 
pSMARTgus_2E5_ΔPCC 1 cat/ aac(3)IV  PCC 1 gene replaced with IMES 
pSMARTgus_2J19 cat Cosmid containing the genomic regions of 
the VDH gene 
pSMARTgus_2J19_ΔVDH cat/ aac(3)IV VDH replaced with IMES 
pSMARTgus_3D17 cat Cosmid containing the genomic regions of 
the CCR 1 gene 
pSMARTgus_3D17_ErythAmp bla/strep cat replaced by bla/strep  
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Name Marker Description 
pSMARTgus_3D17_ΔCCR  cat/ aac(3)IV CCR replaced with IMES 
pSMARTgus_3J4 cat Cosmid containing the genomic regions of 
the MCM gene 
pSMARTgus_3J4_ΔMCM cat/ aac(3)IV MCM replaced with IMES 
 
2.1.10. Bacterial strains 
Table IV.10: Bacterial strains (E. coli and Streptomyces) used in this work 
Strain Description 
Del1 S. albus J1074 lacking the CCR 2 gene (Myronovskyi et al. 
2014b) 
Del1ΔccrD1-1 Del1 strain with the CCR 1 gene knocked out by IMES  
Del1ΔccrD1-1 / R2 Strain with deleted CCR and integrated pamamycin R2 cosmid 
Del1ΔccrD1-1 ΔMCM CCR 1 + 2 and MCM knocked out by IMES 
Del1ΔccrD1-1 ΔMCM / R2 Strain with deleted CCR and MCM and integrated pamamycin 
R2 cosmid 
Del1ΔccrD1-1 ΔMCM ΔPCC 1 CCR 1 + 2, MCM and PCC 1 knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 1 CCR 1 + 2 and PCC 1 knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 2 CCR 1 + 2  and PCC 2 knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 2 ΔMCM CCR 1 + 2, PCC 2 and MCM knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 2 ΔMCM 
ΔPCC 1 
CCR 1 + 2, PCC 1 + 2 and MCM knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 2 ΔMCM 
ΔPCC 1 / R2 
Strain with deleted CCR, PCC, MCM and integrated 
pamamycin R2 cosmid 
Del1ΔccrD1-1 ΔPCC 2 ΔMCM 
ΔPCC 1 ΔVDH 
CCR 1 + 2, PCC 1 + 2, MCM and VDH knocked out by IMES 
Del1ΔccrD1-1 ΔPCC 2 ΔMCM 
ΔPCC 1 ΔVDH / R2 
Strain with deleted CCR, PCC, MCM, VDH and integrated 
pamamycin R2 cosmid  
Del1ΔccrD1-1 ΔPCC 2 ΔPCC 1 CCR 1 + 2, PCC 1 and 2 knocked out by IMES 
ET12567 pUB307 E. coli strain ET12567 (MacNeil et al. 1992) transformed with 
pUB307 (Bennett et al. 1977) used for conjugation 
GB05red  E. coli strain derived from GB2005 by integration of genes 
necessary for λ-mediated recombination  
S. albus J1074 Isoleucine-plus-valine auxotrophic derivative of S. albus G 
(Chater & Wilde 1976b), lacking SalI-restriction activity 
S. albus J1074 / R2 S. albus J174 with integrated pamamycin R2 cosmid 
S. albus J1074 ΔVDH S. albus J1074 with VDH knocked out by IMES 
S. albus J1074 ΔVDH / R2 S. albus J1074 strain with deleted VDH and integrated 
pamamycin R2 cosmid 
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2.2. Methods 
2.2.1. Methods in microbiology 
2.2.1.1. Strain maintenance 
Streptomyces strains were stored at – 80 °C. For this, the strains were grown in a 500 ml-
Erlenmeyer flask with one buffle filled with 100 ml of NL410 (Table IV.4). The flask was 
inoculated with spores and grown for at least 72 hours at 28 °C, 180 rpm. 0.8 ml of the culture 
was mixed with 0.8 ml of the sterile conservation solution (Table IV.5) mixed and frozen.    
2.2.1.2. Cultivation conditions 
2.2.1.2.1. Preculture 
100 ml of NL 410 were inoculated with spores and cultivated for 48 hours at 28 °C, 180 rpm in a 
500 ml-Erlenmeyer flask. 
2.2.1.2.2. Main culture 
100 ml of the respective media was inoculated with 6 % of the preculture medium and cultivated 
for 72 hours at 28 °C, 180 rpm.  
2.2.1.2.3. Optimization of NL SGG for pamamycin production 
The influence of different carbon / nitrogen sources on pamamycin production was tested by 
modifying the NL SGG medium. 
Table IV.11: Media composition for the media variation test 
 NL SGG Variation I Variation II Variation III Variation IV 
Starch soluble 10 g --- --- --- --- 
Cornsteep 
powder 
2.5 g --- --- --- --- 
Yeast extract 2 g --- --- --- --- 
NaCl 1 g --- --- --- --- 
CaCO3 3 g --- --- --- --- 
Glucose 10 g Glucose 15 g Maltose 20 g Glucose 15 g Maltose 20 g 
Glycerol 10 g Glycerol 15 g --- Glycerol 15 g --- 
Bacto peptone 15 g --- --- Soymeal 10 g Soymeal 10 g 
Tap water 1.0 l --- --- --- --- 
pH 7.3 --- --- --- --- 
 
 
 
IV. Strain development of Streptomyces albus J1074 for pamamycin production 
 
 
43 
 
2.2.1.2.4. Pamamycin production dependency on O2 level 
Pamamycin production in dependency on O2 level was determined by using different shaking 
flasks, amount of medium and rotation speed. There were 10 different combinations, sorted by O2 
level. 
1. 100 ml medium; flask without buffle; 120 rpm 
2. 100 ml medium; flask without buffle; 180 rpm 
3. 50 ml medium; flask without buffle; 120 rpm 
4. 50 ml medium; flask without buffle; 180 rpm 
5. 150 ml medium; flask with 1 buffle; 120 rpm 
6. 150 ml medium; flask with 1 buffle; 180 rpm 
7. 100 ml medium; flask with 1 buffle; 120 rpm 
8. 100 ml medium; flask with 1 buffle; 180 rpm 
9. 100 ml medium; flask with 4 buffles; 120 rpm 
10. 100 ml medium; flask with 4 buffles; 180 rpm 
2.2.1.2.5. Pamamycin production curve 
To determine when pamamycin production reaches its maximum during cultivation, the S. albus 
J1074 / R2 strain was cultivated as described in IV.2.2.1.2.1 and IV.2.2.1.2.2 and samples were 
taken at 0 h, 3.5 h, 7 h, 10 h, 14 h, 24 h, 27 h, 31 h, 34 h, 38 h, 48 h, 51 h, and 53 h.  
2.2.1.2.6. Influence of ammonium ions and L-Valine on VDH activity 
To test the influence of ammonium ions or L-Valine on the activity of the VDH, 50 mM 
ammonium acetate or 50 mM L-Valine were added to the cultivation medium after sterilization. 
2.2.1.2.7. Influence of succinate on pamamycin production 
The influence of succinate on pamamycin production was tested by adding 100 µM, 500 µM, 10 
mM and 50 mM sodium succinate to the medium after sterilization. 
2.2.2. Secondary metabolite analytics 
2.2.2.1. Extraction of pamamycin 
10 ml of the main cultures were collected in a 15 ml tube and separated by centrifugation for 10 
minutes at 8000 rpm. 5 ml of supernatant were transferred to a new 15 ml tube and extracted with 5 ml 
ethyl acetate for 30 minutes on a shaking incubator. The remaining biomass was extracted with 10 ml 
of a mixture of methanol and acetone (1+1) for 30 minutes on a shaking incubator. Both the 
supernatant and biomass extracts were evaporated to dryness using a sample concentrator. The 
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supernatant extract was then resolved in 500 µl of methanol. The biomass extract was resolved in 1000 
µl of methanol. Both kinds of extracts were diluted with DMSO (1+1) prior to HPLC measurement.  
2.2.2.2. Dry weight calculation 
To determine the dry weight, 1 ml of the main culture was collected in a previously weighted 1.5 
microtube and dried at 65 °C for 24 h. After the liquid has evaporated, the tube was weighed again. 
2.2.2.3. HPLC Data Analysis 
Measurements were performed using a 100 mm BEH C18 column (Waters, Milford, USA) with a flow 
rate of 0.55 ml/min and the following gradient: 0 min 20 % D, linear gradient to 3 min 97 % D, linear 
gradient to 11 min 100 % D (solvent C: 90 mM ammoniumformiate, solvent D: acetonitrile/100 mM 
ammoniumformiate (80 + 20)).   
Pamamycin production was measured by the change in adsorption of the derivative PMM 607, which 
was chosen because of the high abundance of this compound and the presence of a synthesized 
standard for this compound. Several other pamamycin derivatives could be detected and behaved 
accordingly 
2.2.3. Methods in molecular biology 
2.2.3.1. Plasmid isolation 
Plasmids and cosmids were isolated by scratching E. coli cells containing the corresponding vector 
from well grown LB-agar plates by adding 12 ml of sterile H2O to the plates, scratching the cells from 
the surface and transferring the cells into new 1.5 ml micro tubes. The tubes were centrifuged at 1000 
rpm and the supernatant was discarded. The cells were resuspended in 100 µl of Buffer 1 (Table IV.5). 
Buffer 1 maintains the pH, protects the DNA by inactivation of nucleases and makes the E. coli cell 
wall more sensitive. 200 µl of Buffer 2 (Table IV.5) were added and the solution was mixed by 
inverting. Buffer 2 is used for lysis of the cells. NaOH denatures the DNA and SDS lyses the cells. 
150 µl of Buffer 3 (Table IV.5) were added and the solution was mixed by inverting the tubes. Buffer 
3 contains acetic acid which neutralizes NaOH and potassium acetate to precipitate the protein 
fraction. This mixture was then incubated for 10 minutes at – 20 °C. After incubation, the tubes were 
centrifuged at 15.000 rpm and the supernatant was transferred to new 1.5 ml microtubes containing 
600 µl of 2-propanol. After mixing, the tubes were centrifuged for 20 minutes at 15000 rpm at 4 °C to 
recover the plasmid DNA. The supernatant was discarded and 600 µl of 70 % ethanol were added to 
remove the salts from the DNA. After centrifugation for 5 minutes at 15000 rpm, the supernatant was 
discarded and the washing step with ethanol was repeated once more. The remains of ethanol after 
discarding the supernatant were removed by pipetting with a 200 µl tip and the pellet was dried at  
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37 °C for 3 minutes. To dissolve the DNA, 30 µl of water was added to the tubes. After dissolving of 
the DNA, the concentration was measured with an Eppendorf photometer. 
2.2.3.2. BAC isolation by MAX BAC 
An overnight (37 °C; 180 rpm) culture of the corresponding E. coli cells containing the BAC of 
interest was inoculated from glycerol stock. 2 ml of the over overnight culture was transferred to a 2 
ml micro-tube and centrifuged at 10000 rpm for 1 minute. The supernatant was discarded and this 
procedure was repeated twice until 6 ml of the culture were processed. The cells were resuspended in 
250 µl of buffer 1 (Table IV.5) and then 250 µl of buffer 2 (Table IV.5) were added to the mixture. 
The solution was carefully mixed and 350 µl of buffer 3 (Table IV.5) were added and the solution was 
carefully mixed again. The tube was incubated on ice for 4 minutes and then centrifuged at 15000 rpm 
and 4 °C for 4 minutes. The supernatant was transferred into new 2 ml micro tubes containing 1 ml of 
2-propanol. The solution was mixed and then incubated at room temperature for 4 minutes. After 
incubation the tubes were centrifuged at 15000 rpm; 4 °C for 10 minutes. The supernatant was 
discarded and 1 ml of 70 % ethanol was added to the pellet. The pellet was gently washed and then 
centrifuged at 15000 rpm for 1 minute. This procedure was repeated once more and then the pellet was 
dried at room temperature for 4 minutes. The pellet was then resolved in 50 µl of H2O. 
2.2.3.3. Measurement of DNA concentration 
DNA concentration was measured according to the Beer-Lambert Law. Due to this, the nucleic acids 
reach their characteristic absorption maximum at 260 nm. Extinction in one unit corresponds to 50 µg 
/ mg of DNA concentration. DNA purity was measured at 280 nm, corresponding to the absorption 
maximum of aromatic amino acids. The ratio between 260 nm and 280 nm may not exceed 1.8. The 
measurements were carried out photometrically with an Eppendorf photometer (Table IV.1).   
2.2.3.4. Chemical transformation 
2.2.3.4.1. Preparation of chemically competent E. coli cells 
For preparation of chemically competent E. coli cells, a glycerol stock of the corresponding cells was 
resuspended in 1 ml of LB, dilutions (1:100 – 1:1000000) were plated on LB-agar and incubated at  
37 °C overnight. A single clone was chosen, picked in 100 ml of LB and incubated at 37 °C, 180 rpm 
overnight. 8 flasks filled with 100 ml of LB were inoculated with 1 ml of the overnight culture and 
cultivated at 37 °C, 180 rpm until an OD600 of 0.7 (+/- 0.1) was reached. Two flasks were distributed on 
4 50 ml tubes and centrifuged at 5000 rpm for 5 minutes. The supernatant was discarded and the 
procedure was repeated until all flasks were distributed on the 4 50 ml tubes. The following steps were 
performed on ice or with centrifuge a precooled to 4°C. The remaining cell pellet was resuspended by 
adding 15 ml of ice-cool sterile 0.1 M MgCl2 and vortexing. The tubes were then filled up to 40 ml 
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with ice-cooled 0.1 M MgCl2, mixed and centrifuged at 5000 rpm for 5 minutes. The supernatant was 
discarded afterwards. 15 ml of ice-cooled sterile 0.1 M CaCl2 was added into two of the 50 ml tubes, 
the cell pellets were resuspended and then transferred into the remaining two tubes and the pellets 
there were also resuspended. The tubes were then filled up to 40 ml with ice-cooled 0.1 M CaCl2, 
mixed and centrifuged at 5000 rpm for 5 minutes. The supernatant was discarded. 15 ml of ice-cooled 
0.1 M CaCl2 / 15 % glycerol was added into one 50 ml tube and the cell pellet was resuspended. The 
resuspended cells were transferred into the remaining 50 ml tube and the cells were resuspended. The 
tube was filled up to 40 ml with ice-cooled 0.1 M CaCl2/15 % glycerol, mixed and centrifuged at 5000 
rpm for 5 minutes. The supernatant was discarded and the remaining cell pellet was resuspended in 5 
ml of 0.1 M CaCl2 / 15 % glycerol. 60 µl aliquots of this cell solution were transferred into new pre 
cooled 1.5 ml micro tubes and then frozen at – 80 °C.  
2.2.3.4.2. Transformation of chemically competent cells by heat shock 
An aliquot of the previously prepared chemically competent cells was thawed on ice. 5 µl of the 
desired vector were added to the cells and mixed gently. This mixture was incubated for 30 minutes on 
ice. After incubation the cells were heat shocked at 42 °C for 1 minute. After heat shock, the cells 
were incubated on ice for 1 minute. 1 ml of 37 °C LB medium was added to the cells and then 
incubated at 37 °C while shaking for 1 hour. Afterwards the cells were plated on the appropriate 
selective medium and incubated at 37 °C for 12 hours.  
2.2.3.5. Intergenic Conjugation of E. coli and Streptomyces 
To introduce the desired vector into the genome of Streptomyces albus J1074, the method of 
intergeneric conjugation was used. This method is based on the RP1 conjugation system with a relaxed 
recipient specificity and imply transfer of DNA from the non methylating E. coli ET 12567 donor 
strain containing the RP1 derivative plasmid pUB307 (Piffaretti et al. 1988) to the recipient 
Streptomyces strain. 
2.2.3.5.1. Strain Preparation 
The desired vector was introduced into the chemically competent E. coli ET 12567 / pUB307 cells by 
heat shock transformation (IV.2.2.3.4.2). The cells were then spread on LB-agar containing 30 µg/ml 
kanamycin for pUB307 and an additional antibiotic matching the resistance of the corresponding 
vector. One of the obtained double resistant clones was picked and spread on a new plate of LB-agar 
containing the corresponding antibiotics and was incubated at 37 °C for 12 hours.  
Streptomyces strains were picked from a well grown agar plate and spread onto a new MS-agar plate. 
The plates were incubated at 28 °C for 72 hours or until sporulation was obtained. 
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2.2.3.5.2. Conjugation 
For intergeneric conjugation between E. coli and Streptomyces, 8 ml of sterile H2O was added to a 
plate of Streptomyces, the spores were scratched and 5 1.4 ml micro tubes were filled with the spore 
suspension. The spore suspension was incubated at 50 °C for 10 minutes. During the 10 minutes 
incubation, 4 ml of sterile H2O were added on each of two plates of E. coli and the cells were 
scratched. The cells suspension was distributed on two 1.5 ml micro tubes per plate and centrifuged at 
1000 rpm for 1 minute. The supernatant was discarded but approximately 60 µl were left in the tube 
and the cells were resuspended in the remaining H2O. After incubation, the Streptomyces spore 
suspensions were centrifuged at 15000 rpm for 5 minutes. The supernatant was discarded and 
approximately 60 µl were left in the tube and the spores were resuspended in the remaining H2O. For 
conjugation, 1 tube of E. coli and 1 tube of Streptomyces spores were mixed and spread on a new MS-
agar plate. These plates were incubated at 28 °C. As a control the Streptomyces spores were plated 
without E. coli. After 10 hours of incubation, the conjugations were overlaid with nalidixic acid to kill 
the E. coli and the antibiotic of which the resistance should be transferred by the vector.  
2.2.3.6. Agarose gel electrophoresis 
For agarose gel electrophoresis, a 1 % agarose gel in 1 x TAE buffer (Table IV.5) was prepared by 
melting 1 g agarose in 100 ml of 1 x TAE buffer. 20 µl of the DNA of interest was mixed with 3 µl of 
loading dye and filled in the gel pockets. The DNA was separated at 120 V in 1 x TAE buffer at room 
temperature. A 1 kb DNA ladder was used to identify the fragment size. After electrophoresis, the gel 
was stained for 15 minutes in a 2 µg / ml ethidium bromide containing water bath. The DNA 
fragments were visualized with a Gel documentation system (Table IV.1).  
2.2.3.7. DNA purification from agarose gels 
After staining the gel in a 0.6 % methylenium blue solution for 30 minutes, the desired fragment was 
cut out of the gel with a scalpel and transferred to a new 1.5 ml micro tube. DNA from this fragment 
was isolated using the Promega ™ Wizard ® Gel and PCR Clean-Up System according to the 
manufacturer’s instructions and eluted in 50 µl of nuclease free water and stored at – 20 °C for further 
use.  
2.2.3.8. Polymerase chain reaction (PCR) 
To amplify desired DNA fragments, polymerase chain reaction was used. The phusion polymerase 
was used to amplify fragments for homologous recombination purposes while dreamtaq polymerase 
was used to amplify fragments for analytical needs. The annealing temperature (TA) was determined 
specifically with a gradient PCR from 62 °C to 72 °C. The standard reaction mixtures and protocols 
used for fragment amplification are shown in tables IV.12 and IV.13. 
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Table IV.12: Standard reaction mixture for PCR used in this work 
 Dream Taq Phusion 
Buffer 5 µl 10 µl 
dNTPs 1 µl 1 µl 
Primer 1 0.5 µl 0.5 µl 
Primer 2 0.5 µl 0.5 µl 
Template 0.5 µl 0.5 µl 
Polymerase 0.5 µl 0.5 µl 
DMSO 2.5 µl 2.5 µl 
H2O 38.5 µl 34.5 µl 
 
Table IV.13: PCR methods used in this work 
 Dream Taq Phusion 
Cycle 
Temperature Time Temperature Time  
Initial denaturation 95 °C 3 min 98 °C 30 sec 1 x 
Denaturation 95 °C 45 sec 98 °C 30 sec 
30 x Annealing TA 30 sec TA 45 sec 
Extension 72 °C 30 sec 70 °C 30 sec 
Final extension 72 °C 10 min 72 °C 10 min 1 x 
Storage 4 °C ∞ 4 °C ∞ ∞ 
 
2.2.3.9. Red / ET Recombineering 
2.2.3.9.1. Fragment preparation for cosmid targeting 
For fragment deletion the primers from table IV.8 labeled Red / ET were used. These primers contain 
a 50 bp long sequence on the 5’-end matching the chromosome, flanking the region which is going to 
be deleted. The 20 bp 3’-end is matching either the right or left shoulder of the disruption cassette.   
To amplify the disruption cassette with the corresponding genome match, a PCR was performed with 
the plasmid containing the disruption cassette as a template and the primers for the corresponding 
gene. These fragments were then purified by gel electrophoresis and eluted from the gel as previously 
described (IV.2.2.3.7). 
2.2.3.9.2. Δ-red mediated recombination in E. coli GB05red 
The vector containing the region to be disrupted was purified using the MaxBAC protocol 
(IV.2.2.3.2). 5 µl of the purified vector were then transformed by chemical transformation into 
chemical competent E. coli GB05red cells and incubated overnight. 
On the next day, one clone was picked into 14 ml of LB medium, with the corresponding antibiotic, 
and incubated at 37 °C; 180 rpm overnight. From this overnight-culture 300 µl were used to inoculate 
14 ml of LB medium. This culture was incubated at 37 °C and 180 rpm until an OD600 of 0.43 was 
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reached. When the OD was reached, the expression of the recombinases was induced by addition of 
400 µl of 10 % L-rhamnose. Afterwards the strain was incubated until an OD600 of 0.8 was reached.  
1.5 ml of the culture was added into a 1.5 ml micro-tube and centrifuged at 10000 rpm for 1 minute at 
2 °C. The supernatant was discarded and again 1.5 ml of the culture were added, centrifuged, the 
supernatant was discarded and the tubes were placed on ice. On ice, the cells were resuspended in 1 ml 
of ice-cold H2O and then centrifuged at 10000 rpm for 1 minute at 2 °C. The supernatant was 
discarded and the cells were again resuspended in 1 ml of ice-cold H2O. This procedure was repeated 
twice. After washing the cells three times, the supernatant was discarded and approximately 20 - 30 µl 
were left in the tube. 2 µl of the previously obtained PCR product were added to the cells and mixed. 
The mixture was then transferred into electroporation cuvettes (1 mm) and incubated at room 
temperature for 3 minutes. After incubation the cells were electroporated at 1800 V. Then 1 ml of LB 
medium was added and the cells were transferred into a new 1.5 ml micro-tube. The transformed cells 
were incubated at 37 °C; 950 rpm for 70 minutes and then spread on LB-agar containing the 
corresponding antibiotics. 
After incubation of the plates at 37 °C for 24 hours, single colonies of transformants were detected and 
one colony was selected. 100 ml of the selective LB-medium were inoculated with this colony and 
incubated at 37 °C and 180 rpm for 12 hours. The cosmid DNA of this colony was isolated using the 
plasmid isolation protocol (IV.2.2.3.1). The recombination was verified by amplification of the 
disrupted fragment by PCR and sequencing. 
2.2.3.9.3. Transfer of the recombined cosmid into S. albus J1074 and selection of 
recombinants 
The cosmids containing the disruption cassette were introduced into E. coli ET12567 / pUB307 by 
chemical transformation (IV.2.2.3.4.2.) and thereafter transferred into S. albus J1074 (or the 
corresponding knockout strains based on S. albus J1074) by intergeneric conjugation (IV.2.2.3.5.2). 
Some of the obtained exconjugants were overlaid with X-Gluc (70 µl per 100 ml) to test for β-
Glucuronidase activity. β-Glucuronidase activity (blue color) is a sign, that a single crossover event 
has occurred. 8 exconjugants were chosen randomly and transferred to new selective MS-agar plates 
(4 exconjugants per plate). After sporulation was achieved, a drop of X-Gluc was placed in between 
the patches to check for β-Glucuronidase activity. One patch with β-Glucuronidase activity was 
chosen and dilutions (1:100000 – 1:10000000) were plated on new selective MS-agar plates 
containing X-Gluc. The appearance of white colonies is a sign for a double crossover event. One white 
colony was selected randomly and spread on a new selective MS-agar plate. Intergeneric conjugation 
of pUWLint31 and the corresponding S. albus J1074 knockout strain was performed. This was done to 
express the recombinase present on pUWLint31 in the knockout strain to excise the disruption cassette 
with the resistance marker (Myronovskyi et al. 2014a). 50 of the resulting exconjugants were picked 
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on new unselective MS-agar. This should result in a loss of pUWLint31 and the resistance it mediated. 
These patches were picked on LB-agar containing the corresponding antibiotic to screen for sensitive 
clones which successfully lost their disruption cassette. Any clone which was not able to grow on the 
selective LB-agar had the resistance cassette successfully excised. 
To check whether the disruption cassette was correctly excised, a PCR was performed with isolated 
chromosomal DNA of the recombined Streptomyces strains and the _seq_ primers from table IV.8. If 
the recombination happened successfully, a PCR product of the “scar” left on the genome should be 
obtained, which is about 300 bp in length. This fragment was separated by gel-electrophoresis 
(IV.2.2.3.6) and isolated from the gel (IV.2.2.3.7). The fragment was sequenced to obtain the exact 
sequence left on the genome. 
The cosmid containing the PCC2 gene did not contain the GUS-gene. Instead of selecting by β-
Glucuronidase activity, the resulting exconjugants were therefore checked by PCR using primers for 
the chloramphenicol gene. The chloramphenicol gene is located on the backbone of the cosmid and is 
still present after a single crossover event but lost after a double crossover event. Except for the 
determination of the crossover events, the exconjugants were treated as previously described. 
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3. Results 
3.1. Pamamycin production in Streptomyces albus J1074 
3.1.1. Heterologous expression of pamamycin cosmids R1 – R4 
The pamamycin cosmids R1 – R4 were brought into S. albus J1074 via intergeneric conjugation 
(IV.2.2.3.5.). Two exconjugants for each cosmid were cultivated in NL SGG and PPM (Hashimoto et 
al. 2005a) (IV.2.1.4.). The extraction and determination of the pamamycin production was carried out 
as described in (IV.2.2.1.2.). The synthesized standard of pamamycin 607 (Wang et al. 2001) was used 
for comparison. S. albus J1074 without a cosmid was used as a negative control to rule out any 
pamamycin production by the native S. albus J1074 host. 
 
Figure IV.5: HPLC-MS chromatogram of the synthesized pamamycin 607. A compound pamamycin 607 with a retention time 
of 6.5 minutes. B the UV-chromatogram of pamamycin 607. C the fractionation pattern of pamamycin 607 in positive mode.  
Figure IV.5 shows the synthesized pamamycin 607 measured with the method described in IV.2.2.2.3. 
This method is an optimized version of the original pamamycin measurement method used for the first 
detection of pamamycin. The two methods only differ in the length of the gradient. The original 
method had a gradient of 30 minutes and the optimized version was shortened to 15 minutes. 
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Figure IV.6: HPLC-chromatograms of the synthesized pamamycin 607, the supernatant extracts of S. albus J1074 with the 
pamamycin cosmids R1 - R4 and S. albus J1074 without the pamamycin cosmid. 
Pamamycin production could be detected in the extracts of three of the four tested cosmids as shown 
in figure IV.6 (Figure IV.6 2, 3 + 5). Only the extracts of cosmid R3 (Figure IV.6 4) did not show 
production of pamamycin 607. The negative control S. albus J1074 without a cosmid (Figure IV.6 6) 
also showed no sign of pamamycin production. 
The major peak in all extracts in comparison to the standard has a retention time shift of + 0.2 
minutes. A peak with the same retention time as the standard could also be detected but it is much 
smaller in comparison. Since both peaks show the same mass, they could be derivatives of pamamycin 
607 produced by Streptomyces albus J1074.  
Based on these results, the strain with the integrated cosmid R2 and the medium NL SGG were 
selected for further experiments because this combination led to the highest production of pamamycin 
607. 
0 5 10 15 20 25 Time [min]
0.0
0.5
1.0
1.5
2.0
2.5
4x10
Intens.
N6_GB6_01_957.d: EIC 392.0-399.0 +MS2(608.4)
2 S. albus J1074 / R1 
3 S. albus J1074 / R2 
4 S. albus J1074 / R3 
5 S. albus J1074 / R4 
6 S. albus J1074 
1 Pamamycin 607 standard 
IV. Strain development of Streptomyces albus J1074 for pamamycin production 
 
 
53 
 
3.1.2. Optimization of NL SGG for pamamycin production 
To further increase the pamamycin production, the carbon and nitrogen sources of NL SGG were 
increased or replaced by different ones. The changes are noted in table IV.11 (IV.2.2.1.2.3.).   
 
Figure IV.7: Production of pamamycin 607 in NL SGG and the modified versions (I - IV). 
The increase of the carbon sources glucose and glycerol from 10 g to 15 g (SGG (I)) increased the 
pamamycin production by 37 % as shown in figure IV.7. The change from 10 g glucose to 20 g 
maltose (SGG (II)) increased the production by 109 %. The change of the nitrogen source from Bacto 
peptone to soymeal leads to a complete loss in production. SGG (II) was chosen for further 
experiments because of the increased pamamycin production. 
3.1.3. Pamamycin production dependency on O2 level 
To test the pamamycin production in dependency of the O2 level, several flasks with different numbers 
of buffles and different volumes of media were cultivated either at 120 rpm or 180 rpm as described in 
IV.2.2.1.2.4. 
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Figure IV.8: Production of pamamycin 607 in NL SGG (II) from little O2 concentration (1) to high O2 concentration (10). 
Pamamycin production is strongly dependent on the O2 level. Concentration 8 in figure IV.8 
corresponds to the standard cultivation conditions and is thus set to 100 %. Below a certain 
concentration of O2, pamamycin production stopped. The different tested conditions did not influence 
pamamycin production fundamentally and thus the standard cultivation conditions were kept 
unchanged. 
3.1.4. Pamamycin production curve 
To determine the optimal cultivation duration, a production curve for pamamycin 607 and 621 was 
created as described in IV.2.2.1.2.5. 
 
Figure IV.9: Production curve for pamamycin 607 and 621. Pamamycin quantities are each displayed by the calculated peak 
area. Supernatant (KF) and biomass (My) were extracted separately. 
Pamamycin production starts between 10 and 14 hours after inoculation of the production medium and 
reaches a plateau at around 24 hours as shown in figure IV.9. Production of pamamycin 607 is stable 
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after 24 hours and does not increase significantly from this point on. Production of pamamycin 621 
increases rapidly from 10 hours to 24 hours but keeps increasing afterwards. The ideal cultivation 
duration for production of pamamycin 607 and 621was determined to be around 48 hours. Other 
pamamycins could also be detected and increased even after cultivation for 48 hours. Thus for further 
studies a cultivation duration of 72 hours was chosen, to ensure sufficient production of all 
pamamycins.  
3.2. Streptomyces albus J1074 strain development for pamamycin 
production 
As described by Rebets et al. (2015), pamamycin biosynthesis utilizes succinyl-CoA, malonyl-CoA, 
methylmalonyl-CoA and ethylmalonyl-CoA from the primary metabolism of the producer strain to 
produce a wide variety of different pamamycins. To deepen the understanding of the pamamycin 
biosynthesis and its precursor supply, several genes, from the primary metabolism responsible for 
extender unit formation, as described by Chan et al. (2009) were knocked out and the pamamycin 
production in these strains was analyzed.  
3.2.1. Identified genes in S. albus J1074 
The genes involved in the formation of methylmalonyl-CoA and ethylmalonyl-CoA were chosen to be 
knocked out to reduce the number of pamamycin derivatives without those extender units.  
Four genes were identified as essential for the production of these extender units:  
The crotonyl-CoA carboxylase / reductase (CCR) which facilitates the formation of ethylmalonyl-CoA 
from crotonyl-CoA. 
The methylmalonyl-CoA mutase, which is responsible for formation of (2R)-methylmalonyl-CoA 
from succinyl-CoA. 
The propionyl-CoA carboxylase which forms (2S)-methylmalonyl-CoA from propionyl-CoA. 
The valine dehydrogenase which is the starting point for the formation of methylmalonyl-CoA from L-
valine.  
These genes were identified by a blast (http://blast.ncbi.nlm.nih.gov) analysis with the corresponding 
gene from Streptomyces coelicolor. 
CCR 1: XNR_5889 Crotonyl-CoA reductase  
CCR 2: XNR_0456 Crotonyl-CoA carboxylase/reductase, ethylmalonyl-CoA producing 
PCC 1: XNR_2273 Acetyl/propionyl CoA carboxylase alpha subunit 
XNR_2274 Acetyl/propionyl CoA carboxylase, beta subunit 
PCC2:  XNR_4211 Acetyl/propionyl CoA carboxylase alpha subunit 
XNR_4212 Acetyl/propionyl CoA carboxylase 
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MCM: XNR_4665 Methylmalonyl-CoA mutase large subunit 
XNR_4666  Methylmalonyl-CoA small subunit 
VDH:  XNR_2839 Valine dehydrogenase 
Six genes could be identified on the genome of S. albus J1074. These are, two genes for CCR, two 
genes for PCC one MCM and one VDH.  
3.2.2. InSilico simulations 
InSilico Biotechnology AG (Meitnerstraße 9, 70563 Stuttgart) performed a knockout simulation for 
some of the corresponding genes with regard to the pathway products of interest and the feasibility of 
the resulting knockout mutants shown in figure IV.10. 
 
Figure IV.10: Knockout simulation for the S. albus J1074 strain development for pamamycin production project by InSiIico 
Biotechnology. ACC, acetyl-CoA carboxylase; BCC, butyryl-CoA carboxylase; CCR, crotonyl-CoA carboxylase / reductase; 
MCM, methylmalonyl-CoA mutase; MSC, methylsuccinyl-CoA carboxylase; PCC, propionyl-CoA carboxylase. 
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The simulations support the assumption that by knockout of CCR, MCM and PCC the pools of 
methylmalonyl-CoA and ethylmalonyl-CoA should be significantly reduced. InSilico also identified 
additional genes which could be involved in formation of these extender units.  
3.2.3. Knockout of the identified genes 
Knockouts of the identified genes (IV.3.2.1.) were performed with the IMES system (Myronovskyi et 
al. 2014a) as described in IV.2.2.3.9. Except for the knockout of the VDH gene in Streptomyces albus 
J1074, all knockouts were done in the Del1 strain described in Myronovskyi et al. 2014b.  
A panel of strains with different combinations of knockouts was created:  
S. albus J1074       (wildtype strain) 
S. albus J1074 ΔVDH      (1 knockout) 
Del1        (1 knockout) 
S. albus J1074 Δccr      (1 knockout) 
Del1ΔccrD1-1       (2 knockouts) 
Del1ΔccrD1-1 ΔPCC1      (3 knockouts) 
Del1ΔccrD1-1 ΔPCC2      (3 knockouts) 
Del1ΔccrD1-1 ΔMCM      (3 knockouts) 
Del1ΔccrD1-1 ΔPCC2 ΔPCC1     (4 knockouts) 
Del1ΔccrD1-1 ΔPCC2 ΔMCM     (4 knockouts) 
Del1ΔccrD1-1 ΔMCM ΔPCC1     (4 knockouts) 
Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1    (5 knockouts) 
Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 ΔVDH   (6 knockouts) 
Proof of knockouts can be found in the appendix. 
3.2.4. Heterologous expression of the pamamycin producing cosmid R2 in 
selected knockout mutants 
3.2.4.1. Measurements of pamamycin production in the CCR mutants 
To determine the influence of the different CCR genes on the pamamycin production, the pamamycin 
cosmid R2 was brought into S. albus J1074, Del1, S. albus J1074 ΔCCR1 and Del1ΔCCRD1-1 by 
conjugation (IV.2.2.3.5.). S. albus J1074 is the wildtype strain with both CCR genes present, the Del1 
strain is lacking the CCR 2 gene, in S. albus J1074 ΔCCR1 the CCR1 gene was knocked out and the 
Del1ΔCCRD1-1 strain is missing both CCR genes. The strains were cultivated as described in 
IV.2.2.1.2. and extracted as described in IV.2.2.2. The different pamamycins are labeled 
corresponding to their molecular weight.  
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Figure IV.11: HPLC-MS chromatograms of the supernatant and biomass extracts from S. albus J1074 and the CCR knockout 
mutants with integrated pamamycin cosmid R2. 
The wildtype strain S. albus J1074 (Figure IV.11 1 + 2) as well as the Del1 strain (Figure IV.11 3 + 4) 
show no significant difference in pamamycin production levels compared to each other. Different 
types of pamamycins can be detected (594, 607, 621 and 635) whereas 607 and 621 are the major 
products.  
1 Supernatant extract from S. albus J1074 / R2. 
2 Biomass extract from S. albus J1074 / R2. 
3 Supernatant extract from Del1 / R2. 
4 Biomass extract from Del1 / R2. 
5 Supernatant extract from S. albus J1074 ΔCCR 1 / R2. 
6 Biomass extract from S. albus J1074 ΔCCR 1 / R2. 
7 Supernatant extract from Del1ΔCCRD1-1/ R2. 
8 Biomass extract from Del1ΔCCRD1-1/ R2. 
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S. albus J1074 ΔCCR1 (Figures IV.11 5 + 6) and the Del1ΔCCRD1-1 strain (Figure IV.11 7 + 8) also 
show similar traits except for the increased production of pamamycin 594 in S. albus J1074 ΔCCR1 
compared to Del1ΔCCRD1-1. These strains differ greatly from S. albus J1074 and Del1 with their 
detectable production of pamamycin 580, their increased production of pamamycin 594, 607 and 621 
as well as the loss of pamamycin 635 production.  
To compare the production levels of the different strains, pamamycin 607 production was quantified. 
 
Figure IV.12: Production of pamamycin 607 in S. albus J1074, Del1, S. albus J1074 ΔCCR1 and Del1 ΔCCRD1-1. 
Pamamycin production of strain S. albus J1074 was set to 100 %. 
Pamamycin 607 production in S. albus J1074 and Del1 show no significant difference as shown in 
figure IV.12, whereas the production in S. albus J1074 ΔCCR1 and Del1ΔCCRD1-1 was increased up 
to 3 times, to 311 %.  
3.2.4.2. Measurement of pamamycin production in the triple knockout mutants 
The Del1 ΔCCRD1-1 strain was used as a basis for further knockouts because of its lacking both CCR 
genes. In this background the MCM, PCC1 and PCC2 genes were knocked out (IV.2.2.3.9.) and the 
pamamycin biosynthetic gene cluster was introduced into these strains via conjugation (IV.2.2.3.5.). 
The strains were cultivated as described in IV.2.2.1.2. and pamamycin production was determined as 
described in IV.2.2.2. 
For a better comparison of the effects of the knockouts, the LC-MS chromatograms of the mutants 
were overlaid with the S. albus J1074 / R2 chromatogram.  
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Figure IV.13: HPLC-MS chromatograms of S. albus J1074 and the triple knockout mutants with integrated pamamycin 
cosmid R2. 
All knockouts shown in figure IV.13 have similar traits, like the lack of pamamycin 635 already seen 
in the ΔCCR1 strains in IV.3.2.4.1. Additionally, most knockout mutants show an increase of 
pamamycin 594, 607 or 621 production. Interestingly, the PCC1 knockout mutant (Figure IV.13 3+ 4) 
shows no increase in pamamycin 621 production like the MCM (Figure IV.13 1 + 2) or PCC2 (Figure 
IV.13 5 + 6) mutants.  
1 Supernatant extract from S. albus J1074 / R2 (red)  
Del1ΔCCRD1-1ΔMCM (green). 
2 Biomass extract from S. albus J1074 / R2 (blue)  
Del1ΔCCRD1-1ΔMCM (green). 
3 Supernatant extract from S. albus J1074 / R2 (red)  
Del1ΔCCRD1-1ΔPCC1 (yellow). 
4 Biomass extract from S. albus J1074 / R2 (blue)  
Del1ΔCCRD1-1ΔPCC1 (red). 
5 Supernatant extract from S. albus J1074 / R2 (red)  
Del1ΔCCRD1-1ΔPCC2 (cyan). 
6 Biomass extract from S. albus J1074 / R2 (blue)  
Del1ΔCCRD1-1ΔPCC2 (brown). 
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Figure IV.14: Pamamycin 607 production in S. albus J1074 / R2, Del1ΔCCRD1-1ΔMCM / R2, Del1ΔCCRD1-1ΔPCC1 / R2 
and Del1ΔCCRD1-1ΔPCC2 / R2. Production of S. albus J1074 / R2 is set to 100 %. 
Pamamycin 607 production is increased in all knockout mutants, as shown in figure IV.14. The PCC2 
knockout mutant with a production increase of approximately 70 % shows the biggest difference. 
3.2.4.3. Measurement of pamamycin production in the penta knockout mutant 
Based on the results of the triple knockouts (IV.3.2.4.2) all knockouts were combined in one strain 
(Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1). The pamamycin gene cluster was brought into this strain by 
conjugation (IV.2.2.3.5). The strain was cultivated (IV.2.2.1.2) and the pamamycin production was 
measured (IV.2.2.2). 
 
Figure IV.15: HPLC-MS chromatogram of the biomass extract from S. albus J1074 / R2 (grey) and Del1ΔccrD1-1 ΔPCC2 
ΔMCM ΔPCC1 / R2 (brown). 
The Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1, shown in figure IV.15, strain shows a significant increase 
in pamamycin 594, 607 and 621 production, whereas production of pamamycin 635 ceased below 
detection level in comparison to S. albus J1074. 
3.2.4.4. Ammonium feeding to S. albus J1074 / R2 and Del1ΔccrD1-1 ΔPCC2 ΔMCM 
ΔPCC1 / R2 
To determine the role of valine in the precursor supply for pamamycin biosynthesis, ammonium was 
fed to the cultures of S. albus J1074 / R2 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2. 
Ammonium was shown to inhibit the valine dehydrogenase activity (Tang et al. 1994) and thus 
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pamamycin production should be blocked or decreased when valine is used as a source for precursor 
production.  
Ammonium was fed prior to inoculation of the main culture as described in IV.2.2.1.2.6., the strains 
were cultivated (IV.2.2.1.2.) and the pamamycin production was determined (IV.2.2.2.).  
 
Figure IV.16: HPLC-MS chromatograms of S. albus J1074 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 with integrated 
pamamycin cosmid R2 with and without addition of 50 mM of NH4+ 
The influence of NH4+ ions on pamamycin production is shown in figure IV.16. Addition of 50 mM 
ammonium inhibits (Figure IV.16 2) or decreases greatly (Figure IV.16 4) pamamycin production in 
comparison to the cultures without addition of ammonium (Figure IV.16 1 + 3).  
1 Biomass extract from S. albus J1074 / R2. 
2 Biomass extract from S. albus J1074 / R2 with 50 mM NH
4
+ 
3 Biomass extract from Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2. 
4 Biomass extract from Del1ΔccrD1-1 
ΔPCC2 ΔMCM ΔPCC1 / R2 with 50 mM NH
4
+. 
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Figure IV.17: Production of pamamycin 607 in strains S. albus J1074 / R2 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2 
with and without addition of 50 mM ammonium. Production of S. albus J1074 / R2 is set to 100 %. 
As shown in figure IV.17, production of pamamycin 607 is increased approximately 500 % in 
Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2 in comparison to S. albus J1074 / R2. Addition of 
ammonium ions reduced pamamycin production almost completely in S. albus J1074 and about 350 % 
in Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2. 
3.2.4.5. Measurement of pamamycin production in the VDH knockout mutants 
The role of the VDH gene in precursor supply for pamamycin production was analyzed by knockout 
of this gene in S. albus J1074 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1. The pamamycin cosmid 
was brought into these strains via conjugation (IV.2.2.3.5.). The strains were cultivated (IV.2.2.1.2.) 
and pamamycin production was determined (IV.2.2.2.). 
 
Figure IV.18: HPLC-MS chromatograms of S. albus J1074 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 with integrated 
pamamycin cosmid R2 with and without knocked out VDH gene. 
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1 Biomass extract from S. albus J1074 / R2. 
2 Biomass extract from S. albus J1074 ΔVDH / R2. 
3 Biomass extract from Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 / R2. 
4 Biomass extract from Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 ΔVDH / R2. 
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As shown in Figure IV.18, pamamycin production is completely blocked by the knockout of the VDH 
gene in either strain (Figure IV.18 2 + 4).  
3.2.4.6. Influence of succinate on pamamycin production 
The influence of succinate on the production of pamamycins was tested by feeding of sodium 
succinate to S. albus J1074 with the integrated pamamycin R2 cosmid prior to inoculation to the main 
culture as described in IV.2.2.1.2.7., cultivated (IV.2.2.1.2.) and the pamamycin production was 
determined (IV.2.2.2.). Baking soda was used as a control to exclude the influence of sodium ions on 
the production of pamamycins. 
 
Figure IV.19: Production of pamamycin 607 in S. albus J1074 / R2 with and without addition of different concentrations of 
succinate or baking soda. Production of S. albus J1074 / R2 without any additive is set to 100 %. 
As shown in figure IV.19, pamamycin 607 production is increased about 70 % when 100 nM succinate 
are fed to the culture. Higher concentrations of succinate also show an increase in production, however 
they do not show further enhancement of production. The control with 50 mM baking soda shows no 
significant effects on pamamycin production.  
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4. Discussion 
4.1. Pamamycin production in Streptomyces albus J1074 
4.1.1. Heterologous expression of pamamycin cosmids R1 – R4 
Heterologous expression is a versatile tool to study antibiotic production. Pamamycin production 
was detected in Streptomyces alboniger DSM 40043 and a cosmid library was created and 
screened for clones containing the entire set of pam genes using two probes flanking the cluster 
(Rebets et al. 2015). Several cosmids were obtained and tested for the production of pamamycins 
in Streptomyces albus J1074. Previous experiments with S. alboniger DSM 40043 showed 
optimal pamamycin production in the media NL SGG and PPM, so these media were used for 
pamamycin production in S. albus J1074. To identify possible pamamycins, the synthesized 
standard pamamycin 607 (Wang et al. 2001) was used as a reference.  
Pamamycin production was observed in S. albus J1074 after introducing the three cosmids  
(R1, R2 and R4). Additional compounds similar to known pamamycins could be detected in the 
three cosmids (R1, R2 and R4), what can be explained by the biosynthetic potential of the 
pamamycin gene cluster to produce several compounds (Natsume et al. 1995). The compound 
with the same retention time as the synthesized standard was the minor peak in all extracts and 
corresponded perfectly to pamamycin 607. With a retention time shift of 0.2 minutes, an 
additional compound could be detected which also corresponded to pamamycin 607. This 
compound was the major product in all extracts.  
The cosmid R2 and the medium NL SGG have been chosen for further experiments because their 
combination yields the highest production of pamamycins.  
4.1.2. Optimization of NL SGG for pamamycin production 
Media composition influences secondary metabolite production greatly (Higashide 1984). To 
increase pamamycin production, different combinations of various carbon and nitrogen sources as 
well as different amounts of them were varied with NL SGG as a starting point. An increase of the 
carbon sources glucose and glycerol from 10 g/l to 15 g/l each also led to an increase of 
pamamycin production by 30 %. An increase of the carbon source and a switch from glucose to 
maltose (10 g/l glucose to 20 g/l maltose) further increased the production of pamamycin by  
100 %. Glucose is generally used in rich media as a fast available carbon source for rapid biomass 
formation, because glucose can be consumed without the need of specific exoenzymes. But 
glucose is not the only carbon source in these media, because of its ability to inhibit antibiotic 
IV. Strain development of Streptomyces albus J1074 for pamamycin production 
 
 
66 
 
production (Sanchez et al. 2010). The switch from glucose to maltose as a rapidly available 
carbon source can explain the increase of production.  
Changing the nitrogen source from Bacto® peptone to soymeal completely abolished the 
production of pamamycins. This can be explained by the increase of nitrogen which has a 
negative effect on antibiotic production like in case of cephamycin and streptomycin (Srinivasan 
et al. 1991).  
Because of its increased pamamycin production, NL SGG (variation II) has been chosen for 
further studies.  
4.1.3. Pamamycin production dependency on the O2 level 
Aeration is very important for the production of secondary metabolites in aerobic organisms. 
Pfefferle et al. (2000) showed that ε-rhodomycinone-production in the fermentation process of 
Streptosporangium sp. NN 22303 increases with higher aeration rate, but drops after a certain 
level. To determine the influence of aeration on pamamycin production in Streptomyces albus 
J1074, several different flasks with different volumes of production medium and different 
rotations speeds were used. The two cultivations without a buffle and 100 ml medium in a 300 ml 
flask showed no pamamycin production, which indicates that pamamycin biosynthesis requires 
extensive aeration. The highest pamamycin production was achieved in a 4 buffle flask with 120 
rpm with an increase of 60 % in comparison to the standard conditions (1 buffle flask, 180 rpm). 
An increase of the rotation speed to 180 rpm in the 4 buffle flask resulted in an increase of 
approximately 20 % in comparison to the standard conditions.  
4.1.4. Pamamycin production curve 
Secondary metabolite production generally starts after the stationary phase of growth or after the 
optimal growth is reached (Bu" Lock et al. 1965). Pamamycin production in S. albus J1074 starts 
between 10 and 14 hours of inoculation and the production maximum for pamamycin 607 and 
pamamycin 621 in the biomass is reached after 30 hours, whereas the pamamycin concentration in 
the supernatant slowly increases over time until the cultures were harvested. Since S. albus J1074 
is a fast growing organism (personal experience) that needs 72 hours to achieve full sporulation in 
comparison to Streptomyces lividans that needs 168 hours, these observations are in accordance 
with the literature. Pamamycin production starts after an optimal growth phase is reached and 
continues to increase over time afterwards until the cultures are harvested. 72 hours was 
determined to be the optimal harvest time, since pamamycin production has reached a sufficient 
production level until then and the cultivation time is considered acceptable.  
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4.2. Streptomyces albus J1074 strain development for pamamycin 
production 
4.2.1. Identified genes in S. albus J1074 
Several important genes for methylmalonyl-CoA and ethylmalonyl-CoA biosynthesis have been 
identified according to the review of Chan et al. (2009)(Figure IV.20) in the fully annotated 
genome of S. albus J1074 (Zaburannyi et al. 2014). 
 
Figure IV.20: Metabolic pathways leading to the formation of (2S)-methylmalonyl-CoA and (2S)-ethylmalonyl-CoA. 
Abbreviations: ICM, isobutyryl-CoA mutase; PCC, propionyl-CoA carboxylase; CCR, crotonyl-CoA carboxylase/reductase; 
MCR, methylmalonyl CoA racemase; MCM, methylmalonyl-CoA mutase; VDH, valine dehydrogenase. 
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As the most important pathways for (2S)-methylmalonyl-CoA biosynthesis the transformation of 
succinyl-CoA to (2R)-methylmalonyl-CoA by the methylmalonyl-CoA mutase (MCM) and 
subsequent rearrangement to (2S)-methylmalonyl-CoA by the methylmalonyl-CoA racemase 
(MCR), the carboxylation of propionyl-CoA to (2S)-methylmalonyl-CoA by the propionyl-CoA 
carboxylase (PCC) and the catabolism of L-valine induced by the valine dehydrogenase (VDH) 
have been identified.  
Ethylmalonyl-CoA is formed by the carboxylation of crotonyl-CoA mediated by the crotonyl-
CoA carboxylase / reductase (CCR).  
A blast search with the corresponding genes from Streptomyces coelicolor revealed one MCM 
gene, two PCC genes, a VDH gene and two CCR genes.  
4.2.2. InSilico simulations 
InSilico Biotechnology AG (Meitnerstraße 9, 70563 Stuttgart) performed knockout simulations 
for the corresponding knockouts based on the metabolomic model of S. albus J1074 they created 
(unpublished data). Their simulations were focused on the production of malonyl-CoA, 
methylmalonyl-CoA, ethylmalonyl-CoA and the liveliness of the cells after the knockouts.  
Their simulations supported the previous decision on target genes for the specific knockouts.  
4.2.3. Knockout of the identified genes 
All identified genes could be knocked out separately or in different combinations of several or all 
target genes and the cells were still viable. As one would suspect, knockout of several genes from 
the primary metabolism responsible for important functions resulted in a reduced fitness of the 
cells but overall the biomass accumulation and growth speed were not impaired significantly. In 
contrast, the time until full sporulation was achieved even decreased slightly. This could be due to 
the reduced fitness and limited supply of cell constituents caused by the knockouts. 
4.2.4. Heterologous expression of the pamamycin producing cosmid R2 in 
selected knockout mutants  
4.2.4.1. Measurements of pamamycin production in the CCR mutants 
There are two CCR genes (CCR 1 and CCR 2) present on the genome of S. albus J1074. To 
determine the function of each of these CCR genes on the production of ethylmalonyl-CoA for 
pamamycin biosynthesis, both genes have been knocked out independently and in combination.  
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The Del1 strain (Myronovskyi et al. 2014b) lacks the CCR 2 gene and the CCR1 gene was 
knocked out in S. albus J1074 resulting in S. albus J1074 ΔCCR 1. The knockout strain with both 
genes deleted was termed Del1ΔCCRD1-1. 
Pamamycin production in the Del1 strain is not significantly altered in comparison to S. albus 
J1074. Both show a comparable compound spectrum and both produce pamamycin 635 which 
utilizes ethylmalonyl-CoA. The CCR 1 knockout mutant S. albus J1074 ΔCCR 1 and the double 
knockout mutant Del1ΔCCRD1-1 show a significantly altered compound spectrum. Not only is the 
production of pamamycin 635 reduced to levels where it is barely detectable, but also the production 
of the remaining pamamycins is increased. In this case pamamycin 607 production is increased by 
about 200 % in the CCR 1 knockout mutant and by about 160 % in the double knockout mutant. 
Pamamycin 580 is also clearly detectable in these strains in comparison to S. albus J1074 and the CCR 
2 knockout strain.  
These results support our assumption that the keto synthase genes from the pamamycin 
biosynthetic gene cluster are promiscuous and incorporate the extender units based on their 
availability. A strain, in which the supply of ethylmalonyl-CoA is reduced or absent, produces less 
or even none of the bigger pamamycins. The increase of production can also be explained by this 
observation. Because of the lack of ethylmalonyl-CoA, malonyl-CoA and methylmalonyl-CoA 
are used for the biosynthesis and thus the products using these extender units are produced in 
greater amounts. 
Interestingly the knockouts show that only the CCR 1 gene participates in ethylmalonyl-CoA 
formation. There are bacterial strains which naturally lack CCR activity like Saccharopolyspora 
erythraea (Stassi et al. 1998) and strains like Streptomyces lividans which have CCR activity (Hu 
et al. 2005). In addition, there are several cases reported of cluster associated CCR genes 
(Haydock et al. 2004; Gandecha et al. 1997; Karray et al. 2007; Haydock et al. 2005) which seem 
to provide additional ethylmalonyl-CoA for biosynthetic production. The genome sequence of  
S. albus J1074 (Zaburannyi et al. 2014) reveals that the CCR 1 gene is located near the core of the 
genome and is not associated to any putative biosynthetic gene cluster, and that the CCR 2 gene is 
located on the outer right arm of the genome and in close proximity to a putative biosynthetic 
gene cluster. S. albus J1074 is one of the strains naturally able to produce ethylmalonyl-CoA via 
the ethylmalonyl-CoA pathway which contains a cryptic cluster that needs CCR activity for 
precursor supply.  
The CCR knockouts also showed that the supply of malonyl-CoA or methylmalonyl-CoA is not 
the bottleneck for pamamycin production since the production is increased when the pool of 
ethylmalonyl-CoA is reduced. Additionally unlike monensin biosynthesis in Streptomyces 
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cinnamonensis (Li et al. 2004) CCR activity does not provide methylmalonyl-CoA for antibiotic 
production in S. albus J1074 under the tested conditions. 
4.2.4.2. Measurement of pamamycin production in the triple knockout mutants 
On the basis of the double CCR knockout strain Del1 ΔCCRD1-1 knockouts of MCM, PCC1 and 
PCC2 were performed, to determine the relevance of these genes on methylmalonyl-CoA biosynthesis 
for pamamycin biosynthesis.  
Like the Del1 ΔCCRD1-1 strain, the triple knockout strains Del1 ΔCCRD1-1ΔMCM, Del1 ΔCCRD1-
1ΔPCC1 and Del1 ΔCCRD1-1ΔPCC2 showed reduced production of pamamycin 635 and an increase 
in production of pamamycins 580, 593, 607 and 621. The increase in production of pamamycin 607 
was ranging from 130 % for the PCC1 knockout to 170 % for the PCC2 knockout. These results are in 
the range of the double CCR knockout.  
None of the knocked out genes showed a significant effect on pamamycin production, which means 
that a knockout of one methylmalonyl-CoA producing gene can be compensated by the remaining 
genes.  
4.2.4.3. Measurement of pamamycin production in the penta knockout mutant 
Since a single knockout of a putative methylmalonyl-CoA producing gene did not show an influence 
on pamamycin production, all identified major genes for methylmalonyl-CoA biosynthesis were 
knocked out in the same background. This strain lacks both CCR, the MCM, PCC1 and PCC2 genes 
resulting in a penta knockout strain termed Del1ΔCCRD1-1 ΔPCC2 ΔMCM ΔPCC1. 
Pamamycin production was measured in this strain and compared to S. albus J1074.  
Like the CCR double knockout mutant or the triple mutants with both CCR genes and either MCM, 
PCC1 or PCC2 knocked out, the penta knockout showed reduced production of pamamycin 635 and 
increased production of the remaining pamamycins. The production of pamamycin 607 and 621 in the 
penta knockout strain was even higher than in any previously obtained knockout mutant.  
Since Streptomyces albus J1074 has the biological potential to form (2S)-methylmalonyl-CoA either 
from the carboxylation of propionyl-CoA (PCC), the rearrangement and epimerization of succinyl-
CoA (MCM) or the catabolism of valine (VDH), the knockout of MCM, PCC1 and PCC2 in the 
background of the CCR knockouts should either lead to a decrease of pamamycin production if 
methylmalonyl-CoA was supplied by any of these pathways, or pamamycin production should be left 
unaltered in comparison to the double CCR knockout if methylmalonyl-CoA was solely provided by 
the catabolism of valine.  
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The increase of pamamycin production in the penta knockout mutant can be explained by the fact that 
a knocked out gene blocks a pathway which indirectly leads to the accumulation of a precursor for 
pamamycin biosynthesis, or some unspecific effects force the bacteria to channel methylmalonyl-CoA 
biosynthesis in one pathway with the result that methylmalonyl-CoA biosynthesis is unspecifically 
increased which in turn facilitates pamamycin biosynthesis.  
The observed increase of precursor supply for pamamycin production is most probably due to the 
knockout of MCM. Knockout of MCM, which rearranges succinyl-CoA to (2R)-methylmalonyl-CoA, 
could lead to an increase of the succinyl-CoA pool in the cell. Since three succinyl-CoA units are 
incorporated into the final pamamycin molecule, this could lead to an increase of production, if 
succinyl-CoA was the bottleneck of pamamycin production. 
4.2.4.4. Ammonium feeding to S. albus J1074 / R2 and Del1ΔccrD1-1 ΔPCC2 ΔMCM 
ΔPCC1 / R2 
To clarify the source of methylmalonyl-CoA for pamamycin production, ammonium was fed to the 
cultures of S. albus J1074 and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 containing the pamamycin gene 
cluster. Ammonium was chosen because of its potential to block VDH activity (Tang et al. 1994).  
Feeding of 50 mM NH4+ showed a nearly complete cessation of pamamycin production in S. albus 
J1074 and a reduction of more than 50 % in the penta knockout strain. This indicates that valine 
catabolism is the source of methylmalonyl-CoA for pamamycin production. 
4.2.4.5. Measurement of pamamycin production in the VDH knockout mutants 
The VDH gene was knocked out in S. albus J1074 and in the penta knockout strain to verify the results 
from the ammonium feeding and to see whether S. albus J1074 was able to compensate the loss of 
methylmalonyl-CoA biosynthesis from the catabolism of valine.  
The knockout of the VDH gene led to a complete cessation of pamamycin production both in S. albus 
J1074 and the penta knockout strain.  
This result shows that the catabolism of valine is the sole provider of methylmalonyl-CoA for 
pamamycin production, and that the strain is not able to compensate the loss of the VDH gene for 
secondary metabolite production. The catabolism of valine has already been described to be important 
for secondary metabolite production (Stevens & Chester 1958; Tang et al. 1994), and pamamycin 
biosynthesis appears to be completely dependent of this pathway under the tested conditions.  
4.2.4.6. Influence of succinate on pamamycin production 
To check if succinyl-CoA is the bottleneck for pamamycin biosynthesis, succinate was fed to S. albus 
J1074 containing the pamamycin biosynthetic gene cluster.  
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Feeding of 100 nM sodium succinate showed a significant increase in pamamycin 607 production of 
66 % which indicates that succinyl-CoA is a limiting factor for the production of pamamycins.  
The higher concentrations of fed succinate also showed a slight increase in production of 38 %, but not 
as much as the lower concentration did.  
Since succinate is an important intermediate of the citric acid cycle, excess of succinate could interfere 
with its balance and in turn meddle with cellular processes. This could have negative effects on 
pamamycin production, what explains the production increase for lower concentrations of succinate.  
 
5. Summary of the strain development of 
Streptomyces albus J1074 for pamamycin 
production 
We could prove pamamycin production in S. albus J1074 after the heterologous expression of 3 of 4 
cosmids obtained by screening for the biosynthetic gene cluster. We optimized the production 
medium, checked O2 consumption and production characteristics of pamamycin. We identified the 
pathways leading to methylmalonyl-CoA and ethylmalonyl-CoA for pamamycin production by 
knocking out the responsible genes. We could determine the level of succinyl-CoA as a bottleneck for 
pamamycin production. We demonstrated this by knocking out the MCM gene, which leads to an 
increase of succinyl-CoA, and by feeding of succinate directly to cultures of S. albus J1074 / R2. A 
panel of knockout strains was created resulting in a final mutant strain which combines six knockouts 
in the same genetic background. The compound profile for pamamycin was heavily influenced and the 
production of some pamamycin derivatives was increased by knocking out specific genes from the 
primary metabolism. In this study we could clearly show the connection between certain pathways of 
the primary metabolism for precursor supply of secondary metabolites. By knocking out certain genes 
we could exploit the promiscuous PKS of the pamamycin biosynthesis to shift the compound spectrum 
into a specific direction. 
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V. An influence of the copy number of 
biosynthetic gene clusters on the 
production level of antibiotics in a 
heterologous host 
1. Introduction 
Heterologous expression, the expression of foreign genes in a suitable host, has been shown to be a 
powerful tool in biotechnology. The principle is to identify genes or clusters of interest and express 
them in a suitable host using an optimized expression system. This method is mostly used if the native 
producer strains or organisms are not genetically accessible and/or show unreliable growth and 
metabolite production profiles. Thus these clusters are preferably expressed in a well-studied model 
organism, where a lot of tools were already successfully applied and cultivation conditions, media 
composition and storage conditions are well described. In fact, heterologous expression has already 
been used to express foreign genes from animals or plants in bacteria or fungi (Frommer & 
Ninnemann 1995), to study the function of genes or clusters (Luzhetskyy et al. 2007; Rebets et al. 
2015), to elucidate unknown genes or pathways (Baltz 2010), to engineer known or unknown 
biosynthetic gene clusters (Wenzel et al. 2005), to generate new derivatives of known compounds 
(Luzhetskyy et al. 2007), to increase the production of desired metabolites (Baltz 2010) or to create 
unnatural pathways (Gomez-Escribano & Bibb 2014). 
It is also a tool of choice to study secondary metabolite production and is widely used in that field for 
many purposes. Some fundamental works base on Actinobacteria. Actinobacteria have been shown to 
not only be a prolific source of natural products (Baltz 2008; Hodgson 2000), but also to be suitable 
hosts for their expression. Several model organisms like Streptomyces albus J1074, Streptomyces 
coelicolor, Streptomyces lividans or Streptomyces griseofuscus have been shown to be fitted for 
specific tasks whereas also industrial derived strains could be useful for heterologous expression 
(Baltz 2010). There are even great efforts undertaken to optimize some of these model organisms to be 
better hosts (Komatsu et al. 2010; Gomez‐Escribano & Bibb 2011; Komatsu et al. 2013). The 
advantage in using model organism for heterologous expression is, that these strains are well 
understood and they are genetically accessible.  
Despite a vast range of available expression hosts, heterologous expression often does not result in the 
desired outcome. Often the yield of the desired product in the heterologous host is significantly lower 
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than in the parental strain (Binz et al. 2008; Huo et al. 2012). To address this problem, additional steps 
have to be made, like introducing promoters upstream of the cluster to force its expression or to 
engineer the precursor supply (Rebets et al. 2015). These steps are quite often not intuitive and very 
time consuming. Toxicity is also a great issue, because the expression hosts are often more susceptible 
to the heterologously produced compounds than the natural producers. This problem can be solved by 
the co-expression of corresponding resistance genes, which also needs time and knowledge about the 
produced substance. 
To address problems like product yield, we integrated additional attB attachment sites of the phage 
ϕC31 into the genome of our heterologous host Streptomyces albus J1074 via Tn5 transposon 
mutagenesis (Petzke & Luzhetskyy 2009). The integration system of this phage (Lomovskaya et al. 
1971) promotes the recombination between the attB site present in the genome of the host and the attP 
site present on the vector (Thorpe & Smith, Margaret C. M. 1998). After incorporation of the 
additional attachment sites into the genome of S. albus J1074 we aim to increase the copy number of 
the integrated gene cluster, and thus to enhance the production of the desired compound.  
Here we present a nonspecific approach to increase the product yield of expressed secondary 
metabolite clusters by addition of attB attachment sites in our heterologous host Streptomyces albus 
J1074. We selected several antibiotic clusters and expressed them in a range of S. albus mutants with 
different numbers of attB attachment sites to study the effect of gene cluster dosage in these strains. 
Furthermore we were able to identify a new aranciamycin derivative produced by one of our mutants.  
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2. Materials and methods 
2.1. Construction of plasmids for transposon mutagenesis 
The hph gene was amplified using pAL1 as a template, Fr-MI-attB-hph as a forward primer, carrying 
attB and the MunI restriction site, and Rs-XI-hph as a reverse primer carrying the XbaI site. The 
amplified fragment was cloned into the MunI and XbaI sites of pTn5Oks resulting in 
pTn5OksattBhph(II). The EcoRV fragment from pTn5OksattBhph(II), containing the transposon, was 
ligated into pNLHim, linearized by EcoRV, to result in pHAT(II)3. 
To verify the obtained construct, analytical restriction mapping with EcoRV was performed. The 
obtained 1,9 kb fragment corresponds to the minitransposon construct cloned from 
pTn5OksattBhph(II). 
Table V.1: Existing plasmid constructs 
Name Description Reference or Source 
pNLTn5 
Replicative vector for actinomycetes containing pSG5-
rep, oriT, and tn5 gene under the tipA promoter 
Dissertation of Dr. Lutz 
Petzke 
p41-2C-06 
pOJ436 derivative, containing aranciamycin 
biosynthetic cluster 
(Luzhetskyy et al. 2007) 
cos2 
pOJ436 derivative, containing the mensacarcin 
biosynthetic cluster 
(Yan et al. 2012) 
DJ380pUp31 
pOJ436 derivative, containing the griseorhodin 
biosynthetic cluster 
(Li & Piel 2002) 
PMM R2 
pOJ436 derivative, containing the pamamycin 
biosynthetic cluster 
(Rebets et al. 2015) 
 
2.2. Introduction of additional attB-sites into S. albus genome  
Additional attB attachment sites were introduced by conjugation of the plasmid pHAT(II)3 into the  
S. albus J1074 chromosome (Protocol for transposon mutagenesis see (Bilyk et al. 2013)).  
The integration was proven by Southern blot.  
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Table V.2: New Plasmid constructs 
Name Vector Size, kb Tns Marker Description 
pHAT(II)3 pNLTn5 11,5 tn5 hph 
Minitransposon with hph, ϕC31-
attB,  R6Kγ origin, flanked by MEs  
pNLHim pNLTn5 9,2 himar1 aac(3)IV 
Plasmid derived from pNL1, 
containing himar1(a) gene 
pTn5Oks n/a 3,6 
himar1, 
tn5 
bla 
PCR-derivative containing  R6Kγ 
origin flanked by two MEs and two 
ITRs (Shine Gene, PRC) 
 
Table V.3: Primers used for plasmid construction 
Name Primer sequence (in 5’->3’) Features 
Fr-MI-attB-
hph 
ccccccaattgCGGGTGCCAGGGCGTGCCCTTGG
GCTCCCCGGGCGCGTACccgtatttgcagtaccagcgt-3 
MunI (in italics), attB (in 
capitals) 
Rs-XI-hph ccccctctagagaataggaacttcggaatagg XbaI (in italics) 
 
2.3. Heterologous expression of the secondary metabolite clusters 
The PMM R2 cluster was obtained by previous work in our group. The cos2 
(didesmethylmensacarcin) and the aranciamycin cosmid 41–2C-06 were obtained from Andreas 
Bechthold. The griseorhodin encoding gene cluster on the cosmid DJ380pUp31 was obtained from 
Jörn Piel.  
All cosmids were brought into E. coli ET 12567 (pUB307) by transformation. The transfer of the 
clusters from E. coli ET 12567 (pUB307) into S. albus J1074, S. albus T1, S. albus T11 and S. albus 
ΔpseB4 was accomplished by intergeneric conjugation (Sambrook & Russell 2001), to obtain  
S. albus::PMM R2, S. albus::cos2, S. albus::41-2C-06, S. albus::DJ380pUp31, S. albus T1::PMM R2, 
S. albus T1::cos2, S. albus T1::41-2C-06, S. albus T1::DJ380pUp31, S. albus T11::PMM R2, S. albus 
T11::cos2, S. albus T11::41-2C-06, S. albus T11::DJ380pUp31, S. albus ΔpseB4::PMM R2, S. albus 
ΔpseB4::cos2, S. albus ΔpseB4::41-2C-06, S. albus ΔpseB4::DJ380pUp31.  
 
V. An influence of the copy number of biosynthetic gene clusters on the production level of antibiotics 
in a heterologous host 
 
 
77 
 
Table V.4: Used strains 
Name Description Reference or Source 
S. albus ΔpseB4 
S. albus J1074 strain with deleted ΔpseB4 
attachment site 
(Bilyk & Luzhetskyy 
2014) 
S. albus J1074 S. albus G mutant  (Chater & Wilde 1976) 
S. albus T1 
S. albus J1074 strain with additional attB 
attachment site introduced by transposon 
mutagenesis 
This work 
S. albus T11 
S. albus J1074 strain with additional attB 
attachment site introduced by transposon 
mutagenesis 
This work 
 
2.3.1. Pamamycin production 
The strains containing the PMM R2 cosmid were cultivated in a preculture medium containing 1 % 
glucose, 1 % glycerol, 0.5 % oatmeal, 1 % soymeal, 0.5 % yeast extract, 0.5 %  Bacto casaminoacids 
and 0.1 % CaCO3 in tap water; the pH was adjusted to 7.0 (1M NaOH) prior to sterilization. The 
production media consisted of glucose 1 %, glycerol 1 %, soluble starch 1 %, corn steep powder 0.25 
%, Bacto peptone 0.5 %, yeast extract 0.2 %, NaCl 0.1 % and CaCO3 0.3 % in tap water; the pH was 
adjusted to 7.3 (5 M NaOH) prior to sterilization. The preculture medium was inoculated using 1/8 of 
a well grown agar plate. The production medium was inoculated with 6 % of the preculture medium. 
The strains were cultivated for 48 h in the preculture medium, transferred to the production medium 
and harvested after 72 h.  
2.3.2. Didesmethylmensacarcin and griseorhodin production 
The strains containing the cos2 or DJ380pUp31 cosmid were cultivated for 48 h in tryptic soy broth 
(TSB, Sigma, Germany) as a preculture medium. The production medium contained 4 % dextrin, 0.75 
% soytone, 0.5 % baker’s yeast, 2.1 % MOPS in deionized water; the pH was adjusted to 6.8 (1 M 
NaOH) prior to sterilization. 100 ml of the preculture medium were inoculated using 1/8 of a well 
grown agar plate. The production medium was inoculated with 6 % of the preculture medium. The 
strains were cultivated for 48 h in the preculture medium, transferred to the production medium and 
harvested after 120 h. All strains were grown at 28 °C; 180 rpm.  
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2.3.3. Aranciamycin production 
The strains containing the 41–2C-06 cosmid were cultivated for 216 h on 30 ml solid medium 
containing 2 % mannitol, 2 % soymeal, 2 % agar in distilled water. The plates were inoculated using 
100 µl of a spore suspension consisting of 1/3 of a well grown plate harvested in 1 ml H2O. 
2.4. Determination of production 
One clone of each strain with the corresponding, integrated secondary metabolite cluster was chosen 
and a preculture was inoculated from spores. From this preculture three flasks of the main culture were 
inoculated to produce three technical replicates for each exconjugant. Cultivation of the pre and main 
culture were performed as previously described in V.2.3.1., V.2.3.2. and V.2.3.3.  
The cultures were harvested, separated by centrifugation and 5 ml of supernatant was extracted with 
ethylacetate. The remaining biomass was extracted with a mixture of methanol and acetone (1+1). 
Both the supernatant and biomass extracts were evaporated to dryness using a rotary evaporator 
(RV10, VWR, Germany). The supernatant extract was then resolved in 500 µl of methanol. The 
biomass extract was resolved in 1000 µl of methanol. The extracts were then measured using a 100 
mm BEH C18 column (Waters, Milford, USA) with a flow rate of 0.55 ml/min and the following 
gradient: 0 min 5 % B, 9 min 95 % B (solvent A: water + 0.1 % formic acid, solvent B: acetonitrile + 
0.1 % formic acid).    
The peak area of the corresponding compound was measured, normalized to biomass and used for 
comparison. For all secondary metabolites, the production of the ΔpseB4 strain with one attachment 
site was set as 100 %. 
2.4.1. Determination of pamamycin production 
The samples were extracted as previously described. Measurement was performed using a 100 mm 
BEH C18 column (Waters, Milford, USA) with a flow rate of 0.55 ml/min and the following gradient: 
0 min 20 % D, linear gradient to 3 min 97 % D, linear gradient to 11 min 100 % D (solvent C: 90 mM 
ammoniumformiate, solvent D: acetonitrile/100 mM ammoniumformiate (80 + 20)).   
Pamamycin production was measured by analysis of the compound area of the derivative PMM 607, 
which was chosen because of the high abundance of this compound and the presence of a synthesized 
standard (Wang et al. 2001). Several other pamamycin derivatives could be detected and behaved 
accordingly.  
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2.4.2. Determination of demethoxyaranciamycinone production 
The agar of each plate was cut into pieces and put into a 50 ml Falcon tube. 10 ml of ethylacetate was 
added and shaken at 180 rpm at 28 °C for 15 minutes. The organic phase was separated from the water 
phase by centrifugation and evaporated. This procedure was repeated three times and the 
corresponding fractions were combined. The extracts were resolved in 1.5 ml of a mixture of 
Methanol and DMSO (2+1) and measured using a 100 mm BEH C18 column (Waters, Milford, USA) 
with a flow rate of 0.55 ml/min and the following gradient: 0 min 5 % B, 9 min 95 % B (solvent A: 
water + 0.1 % formic acid, solvent B: acetonitrile + 0.1 % formic acid). 
2.5. Production and isolation of 2-(1-hydroxyethyl)-1,8-dihydroxy-
3-methylanthraquinone 
The preparative production of 2-(1-hydroxyethyl)-1,8-dihydroxy-3-methylanthraquinone was carried 
out on 120 x 120 x 17 mm square petri dishes (Greiner bio-one, Germany) containing approx. 50 ml of 
MS medium (1 % mannitol, 1 % soymeal, 1 % agar in deionized water). The plates were inoculated 
with 1 ml of spores of S. albus T11::41-2C-06 and cultivated at 28 °C for 168 h. 58 plates were 
prepared.  
For extraction, the agar was cut and filled into 2 two L bottles (Schott). The agar was extracted three 
times with 750 ml of ethylacetate. After each step the agar was filtered to remove the ethylacetate. The 
resulting extracts were combined yielding 4.5 L of the extract. This extract was reduced to dryness on 
a rotary evaporator and resolved in 13 ml of methanol. This methanol solution was further separated 
using our semiprep HPLC system using a NUCLEODUR C18 HTec column (Waters, Milford, USA) 
with a flow rate of 5.6 ml/min and a linear gradient: 0 min 5 % B to 20 min 100 % B (solvent A: water 
+ 0.1 % formic acid, solvent B: acetonitrile + 0.1 % formic acid). 
 
2.6. Structure elucidation of 2-(1-hydroxyethyl)-1,8-dihydroxy-3-
methylanthraquinone 
Mass spectra were recorded using a Thermo Finnigan LTQ Orbitrap mass spectrometer. NMR spectra 
were measured using a Varian VNMR-S 600 equipped with 3 mm triple resonance and 3 mm dual 
broadband probes in CDCl3 at T = 25 °C. The residual solvent signals were used as internal reference 
(δH = 7.25 ppm, δC = 77.0 ppm). 
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3. Results and Discussion 
3.1. Introduction of additional attB-sites into the genome of 
Streptomyces albus J1074 
Heterologous expression of biosynthetic gene clusters in streptomycetes very often involves the ϕC31-
based integration system. Integration vectors should contain the attP site for integration and the 
integrase encoding gene. The recipient chromosome typically carries an attachment attB site for 
successful integration of the vector. In our previous studies (Bilyk & Luzhetskyy 2014), we have 
shown that S. albus J1074 contains two highly active attB sites, which partially explain its excellent 
features as a heterologous host for the expression of biosynthetic gene clusters. The heterologous 
production of aranciamycin is significantly reduced when one attB site was deleted from the 
chromosome of S. albus J1074. In order to investigate the correlation between the copy number of an 
antibiotic cluster and the heterologous production of the corresponding antibiotic, we decided to 
introduce additional copies of the attB site into the chromosome of S. albus J1074 using transposon 
integration. With this aim a primer containing attB was used for the amplification of the hygromycin 
resistance gene from pAL1. The obtained PCR-fragment was cloned into pTN5Oks synthesised 
previously (Table V.3). Thus, a Tn5-transposon containing attB and the hygromycin resistance gene 
was obtained. This transposon was cloned into EcoRV-linearized pNLTn5, resulting in pHAT(II)3. 
The plasmid was introduced into S. albus J1074 by intergeneric conjugation, transposon mutagenesis 
was carried out according to the protocol described previously (Bilyk et al. 2013) and eleven mutants 
with randomly inserted attB sites were isolated and analysed by Southern hybridization. The 
hygromycin resistance gene was used as a selection marker. According to the results (Figure V.1) it 
was speculated that mutant #11 has more than one integration of the transposon into the genome. 
Thus, this mutant, marked as T11 and one mutant with one copy of the transposon, marked as T1, 
were taken for further analysis. To summarize, a set of four strains with the number of attachment sites 
ranging from one (pseB4-strain) to four (T11-strain) was obtained. 
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Figure V.1: Southern hybridization of S. albus J1074 with integrated pHAT(II)3 
 
 
 
                  
                         M      1       2  
 
 
A B 
Figure V.2: The map (A) and analytical restriction (B) of pHAT. (A) Plasmid contains following features: oriT – origin of 
plasmid transfer; pSG5rep – actinomycetes temperature-sensitive replicon; tn5(a) – synthetic transposase gene, under 
control of tipAp – thiostrepton inducible promoter; aac(3)IV – apramycin resistance marker; hph – hygromycin resistance 
marker; ME – mosaic end recognition sequence for transposase; R6Kγ-ori – origin for rescue cloning; attB – ϕC31 phage 
attachment site. (B) M - 1kb DNA Ladder; 1 – undigested plasmid; 2 – plasmid digested with HindIII and XbaI. The 
transposase fragment is visible as 1,5 kbp and the backbone as 10 kbp. 
3.2. Heterologous expression of pamamycin, aranciamycin, 
mensacarcin and griseorhodin 
Four secondary metabolite clusters for the biosynthesis of pamamycin, mensacarcin, aranciamycin and 
griseorhodin (Figure V.3) were brought into all four S. albus J1074 mutant host strains, delta pseB4, 
wild type, T1 and T11 by intergenic conjugation. The integration of the corresponding secondary 
metabolite cluster was confirmed by apramycin resistance conferred by the integrated cosmids, PCR 
and HPLC-MS profile.  
1    2   3    4    5   6   7   8    9  10  11 12  13 14  15 
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During work with these strains, several observations were made. Conjugation efficiency in the ΔpseB4 
strain was slightly increased whereas it was severely reduced in T1 and T11 in comparison to the  
S. albus J1074 wild type strain. In our previous study, we have shown that the integration of the ϕC31 
based constructs occurred in all available attB sites within the S. albus chromosome. Since integration 
into additional sites is harder to achieve for the strain, the integration efficiency dropped significantly 
in the T1 and T11 strains in comparison to the S. albus J1074 strain and increased for the ΔpseB4 
strain (Bilyk & Luzhetskyy 2014). 
 
Figure V.3: Structures of the secondary metabolites used in this work. Products with the corresponding cosmid: Pamamycin-
607 (PMM R2), Griseorhodin A (DJ380pUp31), Mensacarcin (cos2), Demethoxyaranciamycinone and 2-(1-hydroxyethyl)-
1,8-dihydroxy-3-methylanthraquinone (41-2C-06) 
The conjugation efficiency also was influenced by the type of the inserted secondary metabolite 
cluster. The integration of the pamamycin biosynthetic gene cluster was less efficient in comparison to 
the other clusters, which could be due to the fact, that pamamycin is a highly active antimicrobial 
compound. The exconjugants with the aranciamycin and griseorhodin clusters could be checked by 
phenotype for their production, since both compounds have a red color, which can be seen around the 
producing clones. The production of all four compounds was confirmed by HPLC-MS of several 
independent clones containing the corresponding gene clusters. All tested exconjugants produced 
pamamycin, whereas in case of aranciamycin, griseorhodin and mensacarcin we have observed clones 
with completely abolished production of the corresponding compound. The S. albus T11::41-2C-06 
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(aranciamycin gene cluster) also differed from the wild type by its lack of spore formation on solid 
medium and the inability to grow in liquid medium.  
 
Figure V.4: Antibiotic production by the corresponding cosmids (PMM R2 for pamamycin, cos2 for DDMM, DJ380pUp31 
for griseorhodin A and 41-2C-06 for demethoxyaranciamycinone) in ΔpseB4 (one attB site), J1074 (two attB sites), T1 (three 
attB sites), T11 (four attB sites). The pamamycin production increases roughly about 100 % for each additional attB site. The 
technical replicates of Strain T1 showed a high diversity ranging from 100 % to 300 % of the ΔpseB4 level. DDMM 
production was increased about 20 % in J1074 and about 40 % in T1. T11 showed a minor increase of about 10 % in 
comparison to ΔpseB4. Production increase for griseorhodin A from one to two attB sites was about 200 %, increase from 
one to three attB sites was 300 %. Strain T11 showed a high diversity between the three replicates and production increase in 
comparison to ΔpseB4 was around 250 %. Production increase for demethoxyaranciamycinone from one to two attB sites 
was about 180 %, increase from one to four attB sites in T11 was 770 %. Strain T1 showed no production of 
demethoxyaranciamycinone. 
The production of pamamycin proved to be greatly influenced by the copy number of the gene cluster 
present in the genome. As seen in figure V.4.A, production increased by approx. 100 % from one to 
two attachment sites. The strains with the additional attachment sites showed even greater increase 
with T11 of about 350 % in comparison to S. albus Δpse4. Strain T1 did not seem to be completely 
stable because of the great fluctuation in production. One of the three technical replicates showed the 
same production level as the ΔpseB4 strain with one attB site, another replicate showed a similar 
production level as the S. albus J1074 strain with two sites, and the third replicate produced amounts 
of pamamycin as expected from a strain with three attachment sites. Production levels were 
accordingly 100%, 200 % and about 350 %. Arguably, some of these replicates may have lost one or 
more clusters during the cultivation.  
Didesmethylmensacarcin (DDMM) production, as seen in figure V.4.B, increased roughly about 20 % 
for two attachment sites. The strains with additional attachment sites showed an increase of 40 % for 
T1 and only a minor increase of 10 % for T11. 
A B
  A 
C
  A 
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Griseorhodin A production, as seen in figure V.4.C, increased from one to two attachment sites around 
200 %. With additional attachment sites the production increased about 300 % for T1 and between 150 
% and 280 % for T11 in comparison to the ΔpseB4 strain.  
Demethoxyaranciamycinone, the product of the aranciamycin gene cluster, was produced on agar 
plates because of the inability of strain T11 to grow in liquid media. This inability could be the result 
of the very high demethoxyaranciamycinone production, which was observed later. The strain T11 
showed weak growth on agar plates and was not able to produce spores even after 14 days of 
cultivation. The other tested strains showed spore formation after 3 days. The production, as seen in 
figure V.4.D, increased around 180 % for S. albus J1074 and around 770 % for strain T11. Strain T1 
did not show any production of demethoxyaranciamycinone but of several byproducts, which could 
also be detected in approximately the same amount in the other strains (data not shown). 
3.3. Production and isolation of 2-(1-hydroxyethyl)-1,8-dihydroxy-
3-methylanthraquinone 
During analysis of the S. albus T11::41-2C-06 extracts, we detected a distinct compound with the 
corresponding molecular ion m/z = 299.09085 ([M+H]+) and a characteristic UV-spectrum of known 
aranciamycins. After comparison with the known aranciamycins and a search in the Dictionary of 
Natural Products, we could not assign this mass to a previously known compound. Probably due to the 
huge increase of the demethoxyaranciamycinone production level in the mutant T11, we could observe 
a significant amount of the previously unknown compound. We decided to purify the unknown 
compound in order to elucidate its structure. 
 
Figure V.5: HPLC-MS run of compound 1. (A) shows the HPLC-MS chromatogram, (B) shows the UV-chromatogram of the 
compound with a retention time of 4.44 min, (C) shows the MS pattern of compound 1. The molecular ion m / z = 339.09122 
[M+H]+ shows the molecular mass of the compound to be 338 gmol-1 
A 
B 
C 
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Since this compound was only a byproduct of demethoxyaranciamycinone, we cultivated S. albus 
T11::41-2C-06 on 58 plates to be able to purify enough material for structure elucidation. After 
extraction and purification by semiprep HPLC we were able to obtain 8 mg of 
demethoxyaranciamycinone and 4 mg of our unknown compound. Both compounds were measured by 
HPLC-MS to determine their exact mass. Figure V.5 shows the HPLC-MS run of 
demethoxyaranciamycinone (Luzhetskyy et al. 2007) with the retention time of 4.44 min. Figure V.6 
shows the HPLC-MS run of the previously unknown compound with a retention time of 5.76 min. 
 
Figure V.6: HPLC-MS run of compound 2. (A) shows the HPLC-MS chromatogram, (B) shows the UV-chromatogram of the 
compound with a retention time of 5.76 min, (C) shows the MS pattern of compound 2. The molecular ion m / z = 299.09085 
[M+H]+ shows the molecular mass of the compound to be 298 gmol-1  
3.4. Structure elucidation of 2-(1-hydroxyethyl)-1,8-dihydroxy-3-
methylanthraquinone 
The mass spectrum of the second compound at rt = 5.76 min show ions with m / z = 299.1 [M+H]+, 
597.2 [2M+H]+ and 619.2 [2M+Na]+ proving the molecular mass to be 298 gmol-1. The molecular 
formula C17H14O5 could be determined from high resolution mass spectrometry (m/z = 299.09085 
form [M+H]+). Combination of 13C NMR and HSQC spectra show 2 methyl groups, 5 methins and 10 
quarternary carbon atoms to be present in the molecule. 2 carbonyl groups (δC = 193.1 and 181.6 ppm) 
show typical values for quinone systems. The 1H NMR spectrum shows 2 chelated phenols (δH = 
11.96 and 12.88 ppm) supporting an anthraquinone substructure. Ring A of the anthraquinone is 
substituted by a hydroxyethyl at C-2 and a methyl group at C-3 proven by HMBC correlations C-2 / 1-
OH, C-2 / 4-H, C-2 / 12-H3, C-2 / 13-H3 and C-3 / 13-H3, C-4 / 13-H3. An isolated methin in position 
C-4 is proven by the singulet at δH = 7.65 ppm supported from HMBC couplings C-10 / 4-H, C-9a / 4-
H and C-13 / 4-H. Ring C of the anthraquinone show one hydroxyl group at C-8, and a ABC system 
A 
B 
C 
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C7-C5, deduced from COSY couplings (5-H / 6-H, 6-H /7-H) and the HMBC signal C-10 / 5-H. 
Therefore the compound could be identified as 2-(1-hydroxyethyl)-1,8-dihydroxy-3-
methylanthraquinone. Tietze et al. (2007) synthesized 2-(1-Hydroxyethyl)-1,8-dimethoxy-3-
methylantharquinone as an intermediate of the chrysophanol analogs.  
 
Figure V.7: Structure elucidation of 2-(1-hydroxyethyl)-1,8-dihydroxy-3-methylanthraquinone 
Since the demethoxyaranciamycinone seems to be very toxic to S. albus, we believe that the new 
compound resulted from the host enzymatic activity in the S. albus T11 strain as a part of a 
detoxification process, because of the high production of demethoxyaranciamycinone.   
 
4. Summary 
We were able to show a clear correlation between attachment sites / number of clusters and production 
level of secondary metabolites. We created a panel of strains for different approaches. Strain ΔpseB4 
could be used to tightly control the expression level of the desired compound or to specifically 
produce only minor amounts of compound if the compound is toxic. For some metabolites it seems 
that gene dosage should not be the only approach to increase the production. For others the number of 
clusters has an accumulative effect and the production can be increased significantly. This approach 
could be used in addition to other approaches to create a range of different expression hosts.  
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VI. Final conclusion 
In this study we were able to sequence the genome of the Streptomyces strain Streptomyces fulvissimus 
and to identify 32 putative secondary metabolite clusters. Besides valinomycin we could also identify 
several different derivatives of nonactin in the extracts of S. fulvissimus cultures and we could also 
link these compounds to the corresponding gene clusters present in the genome. The nonactin gene 
cluster helped to elucidate the pamamycin biosynthesis. Pamamycin derivatives were found in the 
extracts of S. alboniger DSM40043 and we were able to obtain several cosmids carrying the 
biosynthetic gene cluster. The cosmids were brought into S. albus J1074 and we were able to 
heterologously express the pamamycin gene cluster. We were able to elucidate the pamamycin 
biosynthesis by knocking out the responsible biosynthetic genes on the producing cosmid and 
measuring the resulting intermediates in the extracts of S. albus J1074 / R2. We could show that 
pamamycin biosynthesis uses 3-oxoadipyl-CoA and either malonyl-CoA or methylmalonyl-CoA as 
starter units and that pamamycin biosynthesis utilizes the unusual starter unit succinyl-CoA. 
Furthermore we showed the promiscuity of several KS which either utilize methylmalonyl-CoA or 
ethylmalonyl-CoA which results in a complex compound spectrum. To simplify the compound 
spectrum, to increase the production and to identify the supplying pathways for pamamycin 
precursors, we identified several pathways from the primary metabolism with the corresponding key 
genes for methylmalonyl-CoA and ethylmalonyl-CoA biosynthesis. We abolished production of the 
bigger pamamycins by knocking out the genes responsible for ethylmalonyl-CoA formation and could 
observe an increase of production of the remaining pamamycin derivatives. The knockouts of the CCR 
genes also revealed the metabolic potential of S. albus J1074 which can either use the glyoxylate cycle 
or the ethylmalonyl-CoA pathway for the biosynthesis of cell constituents. The knockout of several 
genes identified as responsible for methylmalonyl-CoA biosynthesis did not lead to a loss or decrease 
of the produced pamamycin derivatives which utilize methylmalonyl-CoA. Only the knockout of the 
MCM gene resulted in an increase of pamamycin production. We could link this production yield to 
the increased amount of available succinyl-CoA present in the cell due to this knockout. We could also 
show that pamamycin production is increased by feeding succinate to producing cultures of S. albus 
J1074, which indicates that succinyl-CoA is the bottleneck for pamamycin production. To clarify the 
source of methylmalonyl-CoA for pamamycin production, ammonium ions, which are shown to block 
the valine dehydrogenase activity, were fed to pamamycin producing cultures of S. albus J1074 / R2. 
Under these conditions, pamamycin biosynthesis was almost completely blocked and we could 
confirm the catabolism of valine as the single source of methylmalonyl-CoA for pamamycin 
production by knocking out the VDH gene. This knockout resulted in a complete cessation of 
pamamycin production. We created several different strains with different amounts of knockouts, what 
finally led to a strain with six knockouts of genes of the primary metabolism in the same genetic 
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background. This knockout strain also showed that there are no pamamycins built without 
methylmalonyl-CoA. Interestingly, the strain with six knockouts was still viable and showed only 
reduced biomass accumulation. Additionally it needed less time until full sporulation was reached. 
Lastly we created a panel of strains with different amounts of attachment sites for heterologous 
expression of secondary metabolite clusters and we could show a clear correlation between the number 
of attachment sites / number of clusters and the production level of secondary metabolites.  
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Appendix 
1. Complete genome sequence of Streptomyces 
fulvissimus 
Streptomyces fulvissimus HPLC-chromatogram (ALL MS+) (Amazon-System): 
 
Figure II.S1: Streptomyces fulvissimus HPLC-chromatogram with distinct masses (nonactins) highlighted 
Nonactin from the Dictionary of Natural Products: 
Nonactin Formula: C40H64O12 MW: 736.938  Peak 737 
Monactin Formula: C41H66O12 MW: 750.965  Peak 751 
Dinactin Formula: C42H68O12 MW: 764.992  Peak 765 
Isodinactin Formula: C42H68O12 MW: 764.992  Peak not detected 
Trinactin Formula: C43H70O12 MW: 779.019  Peak 779 
Isotrinactin Formula: C43H70O12 MW: 779.019  Peak not detected 
Tetranactin Formula: C44H72O12 MW: 793.046   Peak not detected 
Orbitrap measurements: 
 
Figure II.S2: Nonactin. 
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Figure IIS.3: Monactin. 
 
 
 
Figure II.S4: Dinactin. 
Appendix 
 
 
105 
 
 
Figure II.S5: Isodinactin. 
 
 
 
Figure II.S6: Trinactin. 
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Figure IIS.7: Tetranactin. 
 
 
 
Figure II.S8: Valinomycin. 
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2. Insights into the pamamycin Biosynthesis 
Table III.S3: pam genes, and their counterparts in non-gene cluster and their predicted function. 
 
Table III.S4: Active site catalytic triad composition of Pam and Non KS enzymes. 
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Table III.S5: Complementation of pam-genes mutations with pam-genes and their counterparts from non-gene cluster. 
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Figure III.S1: Structural features of described pamamycins 
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Figure III.S2: LC-MS traces of extracts from S. alboniger DSM40043 wild type (blue) and ΔpamD mutant (brown). 
Metabolites were extracted and analyzed as described previously. The ΔpamD strain was not able to produce pamamycins. 
Different groups of pamamycins are marked by their molecular mass. 
 
Figure III.S3: Pamamycins production in S. albus J1074 (blue). Pamamycins are marked by their molecular mass. 
chemically synthesized pamamycin 607 (0.015 μM) was used as standard (red). LC-MS analysis of combined extract from 
biomass and cultural liquid is shown. 
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Figure III.S4: LC-MS analysis of metabolites accumulated by S. albus R2 ΔpamJ, ΔpamK and ΔpamL strains. These enzymes 
are involved in the last steps of pamamycin biosynthesis, thus deletion of any of them led to accumulation of the 
intermediates of the pathway hydroxy acids S and L. Different hydroxy acids S and L are marked by their molecular mass. 
Structures of different species of hydroxy acids S, L and K accumulated by different pam gene mutants are predicted based 
on structures of known pamamycins 
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Figure III.S5: LC-MS analysis of metabolites accumulated by S. albus R2 ΔpamY and ΔpamX strains. These enzymes are 
performing amination and methylation steps in pamamycin biosynthesis. Accumulation of hydroxyl acids K rather than non-
aminated pamamycins indicates that these reactions take place before cyclization of final compound but after the formation 
of hydroxyl acid K. Different hydroxy acids K are marked by their molecular mass. Explanation of structural feature of 
identified hydroxy acids K are showed on Figure S4. 
 
Figure III.S6: LC-MS analysis of metabolites accumulated by S. albus R2 (upper panel) and ΔpamC (lower panel) strains. 
Deletion of pamC gene led to decrease in pamamycins production as well as caused changes in the structural range of 
accumulated metabolites. 
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Figure III.S7: Pamamycin production by S. albus R2 and S. albus R2ΔpamA strains. Deletion of pamA did not lead to 
complete cessation of pamamycins production but affects the level of production and spectra of produced compounds. This is 
caused by supply of 3-oxoadipyl-CoA from the primary metabolism of S. albus. Production of several pamamycins implicates 
methyl-adipyl-CoA that cannot be supplied by the host strain. This causes perturbations in spectra of pamamycins 
synthesized by the mutant strain. 
 
Figure III.S8: Production of pamamycins by S. albus AdCoA R2 (blue), S. albus J1074 R2ΔpamA (green) and S. albus 
AdCoA R2ΔpamA (red). Since deletion of XNR_0219 and XNR_0220 blocked supply of 3-oxoadipyl-CoA from the host 
primary metabolism, only trace amounts of pamamycin 607 and two 621 were found in extracts from S. albus AdCoA 
R2ΔpamA. 
 
Appendix 
 
 
114 
 
 
Figure III.S9: SDS PAGE of PamA protein. Lines: 1 Protein marker; 2. Soluble fraction; 3. Insoluble fraction; 4. Column 
flow (unbound proteins); 5. Washing, step 1 (no imidazole); 6. Washing, step 2 (80mM imidazole); 7. Eluted protein; 8. 
Protein samples after concentration and buffer exchange. 
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Figure III.S10: HILIC-MS analysis of PamA reaction mixture and purified product of reaction. Substrates and products are 
marked as CoASH (grey), Mal-CoA–malonyl-CoA (red), Succ-CoA–succinly-CoA (blue) and Ad-CoA–adipyl-CoA (green). 
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Figure III.S11: HILIC-MS analysis of PamA reaction mixture and purified product of reaction. Substrates and products are 
marked as CoASH (grey), MMal-CoA–methylmalonyl CoA (brown), Succ-CoA–succinly-CoA (blue) and MAd-CoA–2-
methyl-3oxoadipyl-CoA (yellow). 
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Figure III.S12: HLLC-MS analysis of PamA competition reaction with methylamalonyl-CoA and malonyl-CoA ration 10:1 
(top) and 1:1 (bottom). The ratio of 3-oxoadipyl-CoA (green) and 2-methyl-3oxoadipyl-CoA (orange) products was found to 
depend on initial ratio of methylamalonyl-CoA and malonyl-CoA when succinily-CoA is not limiting factor (60 mM in 
reaction). 
 
 
Figure III.S13: Feeding of hydroxy acids S and L to S. albus R2ΔpamB (green) and S. albus R2 ΔpamL (purple). As control 
extracts of S. albus R2ΔpamB (orange) and S. albus R2 ΔpamL (blue) were used. Feeding of mixture of hydroxy acids S and 
L to the strain expressing pamL S. albus R2ΔpamB resulted in accumulation of pamamycins. In the same time, strain with 
deleted pamL S. albus R2 ΔpamL gene was not able to activate free hydroxyl acids to complete the biosynthesis of antibiotics. 
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3. Strain development of Streptomyces albus J1074 
for pamamycin production 
Gel picture for Del1ΔccrD1-1 ΔPCC1, Del1ΔccrD1-1 ΔPCC2 and Del1ΔccrD1-1 ΔMCM 
 
FigureIV.S1: Gel picture of the PCR products for MCM (240 bp), PCC1 (265 bp) and PCC2 (281 bp) knockout sind the 
Del1ΔccrD1-1 strain after marker excision. 
Sequencing results for Del1ΔccrD1-1 ΔPCC1, Del1ΔccrD1-1 ΔPCC2, Del1ΔccrD1-1 ΔMCM, 
Del1ΔccrD1-1 ΔPCC2 ΔPCC1, Del1ΔccrD1-1 ΔPCC2 ΔMCM and Del1ΔccrD1-1 ΔMCM ΔPCC1 
and Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 
 
Figure IV.S2: Alignment of the Del1ΔccrD1-1 ΔPCC1 sequencing results to the corresponding genome sequence. 
 
Figure IV.S3: Alignment of the Del1ΔccrD1-1 ΔPCC2 sequencing results to the corresponding genome sequence. 
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Figure IV.S4: Alignment of the Del1ΔccrD1-1 ΔMCM sequencing results to the corresponding genome sequence. 
 
Figure IV.S5: Alignment of the Del1ΔccrD1-1 ΔPCC2 ΔPCC1 sequencing results to the corresponding genome sequence. 
 
Figure IV.S6: Alignment of the Del1ΔccrD1-1 ΔPCC2 ΔMCM sequencing results to the corresponding genome sequence. 
 
 
Figure IV.S7: Alignment of the Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 sequencing results to the corresponding genome 
sequence. 
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Gel picture for Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 ΔVDH and S. albus J1074 ΔVDH 
 
Figure IV.S8: Gel picture of the PCR products for the VDH (212 bp) knockout in the Del1ΔccrD1-1 ΔPCC2 ΔMCM ΔPCC1 
and S. albus J1074strain after marker excision. 
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4. An influence of the copy number of biosynthetic 
gene clusters on the production level of antibiotics 
in a heterologous host 
 
 
 
Figure 4.1: Aerial mycelium and spore formation in S. albus ΔpseB4::41-2C-06 (1), S. albus J1074::41-2C-06 (2), S. albus 
T1::41-2C-06 (3) and S. albus T11::41-2C-06 (4). Intensity of the red color, which originates from the production of 
demethoxyaranciamycinone and derivatives, increases from 1 to 4. In 4 there is no visible spore formation and the strain is 
growing weaker in comparison to 1, 2 and 3. 
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Table 4.1: NMR data of 2-(1-hydroxyethyl)-1,8-dihydroxy-3-methylanthraquinone (600 / 150MHz, CDCl3, T = 25°C, solvent 
as internal reference) 
pos. δC 
ppm 
δH ppm (J Hz) COSYa HMBCa 
1 160.6   1-OH, 13-H3 
1-OH  12.88 s   
2 137.8   1-OH, 4-H, 12-H3, 13-H3 
3 145.3   13-H3 
4 122.9 7.65 s (13-H3) 13-H3 
4a 131.4    
5 120.0 7.82 d (7.6) 6-H 6-H, 7-H 
6 137.3 7.68 t (8.0) 5-H, 7-H 5-H, 7-H, (8-OH) 
7 124.7 7.29 d (8.4) 6-H 5-H, 8-OH 
8 162.5   6-H, 7-H, 8-OH 
8-OH  11.96   
8a 115.8   5-H, 7-H, 8-OH 
9 193.1   (4-H), (5-H) 
9a 114.3   1-OH, 4-H 
10 181.6   4-H, 5-H 
10a 133.6   6-H 
11 66.9 5.16 br t (6.8) 12-H3 (4-H), 12-H3 
11-OH  3.86 br s   
12 22.2 1.62 d (6.8) 11-H 1J 
13 20.6 2.47 s (4-H) 1J, 4-H 
aweak signals in brackets 
 
 
